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Summary 
 
The intraerythrocytic stages of the Plasmodium falciparum life cycle are exclusively 
responsible for all clinical symptoms of malaria. Both children and adults that are 
infected with P. falciparum can either have symptoms of variable severity or be 
asymptomatic. However, it is mostly young children who suffer from severe 
symptoms ranging from severe anaemia to cerebral malaria, and it is mostly adults 
from endemic areas who experience comparatively mild episodes with headache 
and sometimes fever.  
The observed morbidity is largely associated with sequestration of parasitized 
erythrocytes (iRBCs) on endothelial cells of host blood capillaries. This 
cytoadherence prevents late stage iRBCs from being cleared by the spleen. Instead, 
iRBCs bind to various host cell receptors such as CD36, ICAM, or CSA leading to 
obstruction of blood vessels, impaired oxygen delivery in affected host organs and 
immunological reactions of the affected tissues. 
The key mediator of sequestration found is the P. falciparum Erythrocyte Membrane 
Protein 1 (PfEMP1). This large parasite derived protein is exported from the parasite 
and trafficked through various membranes and through the host cell cytosol until 
becoming inserted into the erythrocyte cell membrane. It is located at the interface 
between parasite and host immune system, and undergoes antigenic variation. 
PfEMP1 is encoded by approximately 60 var genes per haploid genome, and is 
expressed in a mutually exclusive manner, i.e. only one gene is expressed at any 
one time. As one of its sophisticated immune evasion strategies, the parasite can 
switch to another PfEMP1 variant and thus becomes no more recognizable by the 
host immune system. 
It is believed that protection against severe malaria is the result of the development 
of immune responses against various variants of PfEMP1. However, immunity to 
malaria is never sterile but instead only reduces parasite density and morbidity. We 
have based our work on the hypothesis that not all variants of PfEMP1 are equally 
pathogenic i.e. have the same affinity to host cell receptors. We believe that only a 
certain subset of PfEMP1 variants is able to confer solid cytoadherence, and 
consequently is responsible for severe malaria. Possessing an antibody repertoire 
against these specific variants therefore will protect from severe episodes. 
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In this work we have chosen a multiple approach to generate molecular tools and to 
test this hypothesis. Firstly, we elaborated on the generation of pan-specific non-
cross reactive PfEMP1 antibodies using both recombinantly expressed domains 
both from the molecule’s head structure (NTS domain) and synthetic peptides 
corresponding to the semi-conserved intracellular part of PfEMP1 (ATS peptides). 
By means of various molecular methods, however, we found that none of the 
generated sera recognized full length endogenous PfEMP1 exclusively. 
Secondly, we attempted expression of large fragments of PfEMP1 in E.coli to test 
the recognition of sera from different malaria cases. At the same time we wanted to 
exploit the possibility to express random fragments of PfEMP1 in a bacterial library 
to similarly test these sera on. Insuperable obstacles with large recombinant protein 
expression forced us to divert our approach towards smaller domains.  
For this we isolated var mRNA from samples from several individuals presenting 
either with asymptomatic infections or experiencing severe malaria episodes. 14 var 
DBL domains were recombinantly expressed in E. coli and used to measure 
antibody titers in sera from 100 semi-immune Papua New Guinean adults. The 
frequency of recognition (FoR) for these antigens of was assessed and compared 
between FoR of DBL domains deriving from severe cases and from asymptomatic 
samples. We found that DBL domains deriving from severe cases were significantly 
more often recognized by sera from semi immune Papua New Guinean adults than 
DBL domains derived from asymptomatic samples. This is indicative for semi-
immune adults not suffering from clinical malaria because being better protected 
against parasites expressing “severe” DBL domains of PfEMP1.  
We also tested 34 sera from children with asymptomatic infections collected during 
a longitudinal study in Tanzania. We selected sera that were collected at two time 
points 6 months apart to assess the development and dynamics of antibodies 
against those DBL domains. FoR increased significantly over time in these children 
but only for DBL domains deriving from severe cases. As these children did not 
suffer from clinical episodes between the two sampling dates, these results also 
indicate that acquisition of antibodies against “severe” DBL domains is faster and 
can confer protection. 
In summary, our findings support the notion that development of antibodies against 
PfEMP1 variants (in this case against DBL domains) is associated with protection 
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against severe disease and thus contributes as an important factor to the acquired 
clinical immunity to severe malaria. These findings raise hope in the feasibility of a 
putative protective vaccine against the major virulence factor PfEMP1. 
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Zusammenfassung 
 
Alleine der intra-erythrozytäre Lebenszyklus von Plasmodium falciparum ist für die 
klinischen Symptome von Malaria verantwortlich. Die Infektion kann sowohl bei 
Kindern, als auch bei Erwachsen symptomlos oder mit verschieden starken 
Symptomen ablaufen. Jedoch sind es meist Kinder, die an den schlimmen 
Symptomen wie schwere Anämie oder cerebraler Malaria leiden. Erwachsene aus 
endemischen Gebieten haben vergleichsweise milde Symptome wie Kopfschmerzen 
und manchmal Fieber.  
Die schweren Krankheitsfolgen sind grösstenteils mit dem Anheften von infizierten 
Erythrozyten an Endothelzellen der Wirtskapillaren verbunden. Diese Zellanheftung 
verhindert, dass die Milz die späten Blutzellstadien herausfiltriert. Infizierte rote 
Blutzellen binden Wirtsrezeptoren wie zum Beispiel CD36, ICAM oder CSA was zu 
einer Verstopfung der Blutgefässe, mangelhafter Sauerstoffzuführung und 
immunologischen Reaktionen im betroffenen Gewebe führt. 
Eine Schlüsselrolle im vermitteln von Zellkontakten hat Plasmodium falciparum 
Erythrozyten Membran Protein 1 (PfEMP1). Dieses grosse Protein, hergestellt durch 
den Parasiten, wird durch mehrere Membranen und das Zytosol des Erythrozyten 
geschleust, bis es in die Erythrozytenmembran eingebaut wird. Es ist so genau an 
der Grenze zwischen dem Parasit und dem Wirtsimmunsystem lokalisiert und macht 
Antigenvariation. PfEMP1 wird von ungefähr 60 var Genen pro haploiden Parasiten 
codiert und wird auf einer sich gegenseitig ausschliessenden Art und Weise 
exprimiert, dass heisst es wird immer nur ein Gen abgelesen. Damit der Parasit das 
Immunsystem umgehen kann, ist er in der Lage auf ein anders var Gen 
umzuschalten. Diese kann dann vom Immunsystem nicht mehr erkannt werden.  
Man glaubt, dass der Schutz vor schwerer Malaria ein Ergebnis der Entwicklung von 
Antikörpern gegen mehrere Varianten von PfEMP1 ist. Aber die Immunität gegen 
Malaria ist nie steril,  sondern reduziert nur die schwere der Erkrankung und die 
Parasitendichte. Die Grundlage unserer Arbeit ist, dass nicht alle Varianten von 
PfEMP1 gleich pathogen sind, dass heisst, nicht alle haben dieselbe Affinität zu den 
Wirtsrezeptoren. Wir glauben, dass nur eine kleine Gruppe von PfEMP1 Varianten 
die Möglichkeit hat eine stabile Zellanheftung auszulösen und dadurch schwere 
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Malaria verursacht. Der Besitz eines Antikörperrepertoires gegen diese Varianten 
würde deshalb gegen schwere Malaria schützen. 
In dieser Arbeit haben wir einen vielfältigen Ansatz verfolgt um molekulare 
Werkzeuge herzustellen und unsere Hypothese zu testen. Als Erstes haben wir 
versucht spezifische, nicht kreuzreaktive Antikörper gegen PfEMP1 zu generieren. 
Wir haben die Kopfstruktur (NTS Domäne) als rekombinantes Protein und als 
synthetische Peptide den teilweise konservierten intrazellulären Teil (ATS Domäne) 
von PfEMP1, als Antigen verwendet. Trotz der Anwendung mehrerer 
molekularbiologischer Methoden konnten wir jedoch kein Serum finden, dass das 
ganze endogene PfEMP1 erkennt. 
Als Zweites, versuchten wir grosse Fragmente von PfEMP1 in E.coli zu exprimieren 
um dann Seren von verschieden Malariafällen darauf zu testen. Zur selben Zeit 
wollten wir zufällige Fragmente von PfEMP1 in einer E.coli Bibliothek exprimieren, 
um die selben Seren darauf zu testen. Unüberwindbare Probleme mit der 
Expression von grossen, rekombinanten Proteinen zwangen uns dazu unseren 
Ansatz in die  Richtung kleinerer Domänen zu konzentrieren.  
Hierfür isolierten wir var mRNS von Proben die aus asymptomatischen und 
schweren Malariafällen stammten. Aus dieser RNS wurden 14 DBL Domänen 
rekombinant exprimiert und die Antikörpertiter von 100 Seren von Erwachsenen aus 
Papua Neu Guinea gemessen. Die Frequenz der Antigenerkennung wurde 
gemessen und zwischen DBL Domänen die aus asymptomatischen und schweren 
Malariafällen isoliert wurden, verglichen. Wir haben herausgefunden, dass DBL 
Domänen die aus schweren Malariafällen stammen signifikant öfter erkannt werden, 
als DBL Domänen, die aus asymptomatischen isoliert wurden. Das ist bezeichnend 
für teilweise immune Erwachsene, die keine klinischen Malariasymptome mehr 
zeigen, da sie gegen die DBL Domänen, die in schweren Fällen exprimiert sind, 
geschützt sind.  
Des Weiteren wurden 34 Kinderseren aus einer logitudinalen Studie aus Tansania 
getestet. Wir haben Seren getestet die an zwei Zeitpunkten gesammelt wurden, 
diese lagen sechs Monate auseinander. Damit konnten wir die Dynamik der 
Antikörperentwicklung beobachten. Die Frequenz der Antigenerkennung ist nur für 
die Gruppe der DBL Domänen die aus Schwerkranken isoliert wurden, gestiegen. 
Da diese Kinder nicht an klinischen Symptomen litten, zeigen diese Resultate, dass 
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Antikörper gegen DBL Domänen die in schweren Fällen exprimiert werden, schneller 
aufgebaut werden und möglicherweise vor schwerer Malaria schützen. 
Zusammenfassend, unsere Ergebnisse unterstützen die Empfindung, dass die 
Entwicklung von Antikörpern gegen PfEMP1 Varianten (in diesem Fall die DBL 
Domäne) die in schweren Malariafällen exprimiert sind, schützend wirken und so zu 
einem wichtigen Faktor der klinischen Immunität beitragen.  Diese Ergebnisse geben 
Hoffnung zur Annahme, dass es möglich ist ein Impfstoff gegen den wichtigsten  
Virulenzfaktor PfEMP1 herzustellen. 
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Introduction 
 
The disease called malaria 
In the year 2002 2,2 billion people were at risk of malaria infection, resulting in over 
500 million clinical cases and more than one million deaths. Sub-Saharan Africa has 
the largest burden of malaria and it accounts for 70% of all malaria cases 
worldwide. Malaria is both a disease of the poor and causes poverty. Poor people 
cannot afford measures to prevent or treat infection and have often no instant 
access to health facilities. In addition, absence from workplace or school because of 
malaria episodes diminishes income and education, which turns the spiral of poverty 
[1, 2]. 
 
Protozoan parasites from the genus Plasmodium cause malaria. Plasmodium 
parasites are transmitted by a bite of an infectious female Anopheles mosquito. 
Malaria is a threat for almost all vertebrates including humans, monkeys, birds, 
reptiles and rodents. Among the numerous different Plasmodium species only four 
can establish a clinically relevant infection in humans: Plasmodium falciparum, 
P.vivax, P. malariae and P. ovale. P. falciparum (malaria tropica, later abbreviated 
malaria) causes the most severe clinical symptoms in humans. The reason for the 
higher virulence compared to the other species is that P. falciparum has the ability 
to adhere to the endothelium of blood vessels thus blocking microcirculation. 
Additionally, it has the highest reproduction rate, releasing up to 24 merozoites per 
cycle and it is able to invade all-age erythrocytes resulting in very high parasitaemia. 
There is no periodicity of fever as it is usually observed in infections in other 
Plasmodium species. P.vivax and P.ovale cause the comparably mild malaria 
tertiana were two fever days are followed by one fever-free day normally without 
major complications. However, P.vivax morbidity and mortality are underestimated 
with up to 80 million cases per year and an increasing trend in mortality in Venezuela 
[3, 4]. Hypnozoites in the liver can cause relapses years after the first manifestation. 
Malaria quartana is induced by P.malariae and causes a four-day fever interval were 
2 days with fever are followed by 2 day without fever. It is also a mild variant of 
malaria but can cause renal complications especially in children.  
 15 
Human infections with P.knowlesi and P.semiovale are possible but very rare 
(personal communication). 
 
Plasmodium falciparum life cycle 
Plasmodium falciparum is a protozoan parasite from the phylum apicomplexa. These 
protists contain a unique set of organelles assembled in the apical complex. The 
apical complex contains the rhoptries, micronemes and dense granules, which are  
vesicular structures that contain enzymes and lipids secreted upon invasion. 
Another distinct and essential organelle is the apicoplast or plastid. The apicoplast is 
surrounded by 4 membranes and is thought to origin from a second endosymbiosis 
of a cyanobacterial chloroplast [as reviewed in 5]. However, in some publications an 
algae is mentioned as ancestor (for example [6]). The apicoplast has its own genome 
and is part of the lipid synthesis system. Most of the apicoplast proteins are 
encoded in the nucleus. It has no photosynthetic activity.  
The lifecycle of P. falciparum is very complex and includes sexual and asexual 
reproduction. It involves two different hosts: a vertebrate e.g. a human and a 
mosquito from the genus Anopheles. The female anopheles injects saliva during a 
blood meal to prevent blood coagulation. Sporozoites are transmitted from the 
mosquito`s saliva into the blood stream of the human. The blood and probably the 
lymphatic system [7] transports the sporozoites into the liver where they invade 
hepatocytes. There they differentiate into hepatic schizonts and multiply (Figure 1 A). 
After 5-14 days the schizont ruptures and releases thousands of merozoites into the 
blood stream, which then invade red blood cells. In the erythrocytes the asexual 
reproduction begins. After invasion the merozoite grows and develops into a small 
ring. The cell is in the G-phase and increases in size. This is the trophozoite stage. 
The transition into the S-phase with DNA duplication and membrane separation 
leads to the schizont, which is the last stage in the erythrocyte. The infected red 
blood cell (iRBC) ruptures and releases around 24 merozoites into the bloodstream. 
The cycle in the red blood cells lasts approximately 48 hours (P.falciparum). All 
clinical symptoms and severe effects are caused by the asexual cycle in the red 
blood cells. Not all merozoites will develop into schizonts. A small number will 
differentiate into male and female gametocytes (Figure 1 B). A female anopheline 
mosquito takes up these gametocytes during another blood meal. In the mosquito’s 
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midgut the female gametocytes develop into macrogametes. The male gametocytes 
exflagellate and form microgametes which fertilize the macrogametes by fusion, 
forming motile zygotes called ookinetes. The diploid ookinetes cross the midgut 
membrane, undergo meiosis and adhere onto the exterior site of the gut wall. Here 
they undergo several rounds of mitosis to form oocysts (sporogony). Each oocyst 
releases thousands of motile haploid sporozoites into the mosquito’s body cavity. 
From there sporozoites migrate into the mosquito’s salivary glands. During a next 
blood meal they are injected together with the saliva into a new host and the cycle is 
completed. 
 
 
Figure 1. Plasmodium falciparum life cycle. 
Schematic representation of the different stages of the life cycle of Plasmodium 
falciparum. In A the exo-erythrocytic cycle taking place in the hepatocytes is shown. 
In B the asexual replication in the erythrocytes and the development of gametocyes 
is shown. In C the cartoon shows the sexual reproduction in the mosquito and the 
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completion of the lifecycle by the inoculation of sporozoites into the vertebrate host 
upon a blood meal (Image modified from: Center for Disease Control and Prevention 
CDC, www.dpd.cdc.gov/dpdx ). 
 
Cytoadherence: Sequestration and rosetting make malaria severe 
The clinical symptoms of malaria are exclusively caused by the asexual replication 
of P.falciparum in red blood cells. The pre-erythrocytic stages in the liver remain 
unnoticed. The common symptom of all malaria infections is high fever induced by 
rupture of infected red blood cells as termination of every cycle of asexual 
reproduction. The pyrogenic compounds released after ruption are grouped 
together as malaria toxins. Glycosylphosphatidylinositol (GPI) and haemozoin are 
the most discussed substances to act as pyrogens. Haemozoin induces 
endogenous pyrogens like TNF-α [8] and IL-1ß [9]. GPI can directly upregulate 
surface receptors like ICAM1 and VCAM1 and induce TNF and IL1 secretion of 
macrophages [10]. Cerebral malaria, a severe form of malaria, is thought to be 
induced by extensive TNF release [11]. 
The parasite is able to remodel the surface of the red blood cell and this remodeling 
enables the parasite to adhere to host endothelia. This causes blood clumping and 
oxygen deprivation of tissues and can lead to organ failure. Briefly, the integration of 
parasite proteins, especially Erythrocyte Membrane Protein 1 (PfEMP1) into the 
erythrocyte plasma membrane mediates the interaction with a variety of host-cell 
receptors. This ability of the iRBC to bind to the vascular endothelium and to 
uninfected RBCs is called cytoadherence. Sequestration of parasites on the inner 
lining of the capillaries is essential for the parasite’s survival, as iRBC would be 
cleared from the blood circulation during spleen passage. The effect for the host, 
however, is severe because the sequestered blood cells clog the thin blood vessels. 
The host receptors which mediate binding to the iRBCs are numerous, including 
CD36, thrombospondin (TSP), VCAM-1, ICAM-1, PECAM/CD31, chondroitin sulfate 
A (CSA) and E-selectin [12-14]. The ICAM-1 receptor might play an important role in 
severe malaria as isolates from patients with cerebral malaria bind this receptor [13]. 
The presentation of ICAM-1 on endothelial cells is upregulated by TNF-α. TNF-α in 
turn is upregulated by the parasite itself as described above. However, the 
interaction between ICAM-1 with an iRBC is not strong enough to mediate binding 
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alone [15] For stable binding other receptors such as CD36 and TSP are needed 
simultaneously [16]. This is supported by experiments where binding of a parasite 
isolate to endothelial cells expressing both CD36 and ICAM-1 was only partially 
blocked by monoclonal antibodies against ICAM-1, but completely abolished with 
incubation of antibodies against both receptors [16].  
A special case of infection is the pregnancy associated malaria (PAM). Semi-
immune adult women, normally protected from severe disease, can develop a 
severe episode upon pregnancy and the fetus development can be impaired. The 
reason is the involvement of the placenta, which represents a new niche for the 
iRBC to adhere. The placenta is often heavily infected with sequestered parasites 
[17-19]. The high parasite load in the placenta is especially dangerous for the fetus, 
as it can lead to growth restriction, decreased birthweight or preterm delivery [20]. 
For the mother malaria infections during pregnancy are associated with severe 
anaemia [21]. This is perhaps induced by TNF release of the monocytes 
accumulated in the placenta. TNF is an inhibitor of erythropoiesis. Additionally 
oxidative stress by nitric oxide alters the erythrocytic membrane and leads to 
increased erythrocyte destruction [reviewed in 22].  
The host receptor involved in placental iRBC sequestration is CSA. Parasites 
extracted from an infected placentas bind to CSA but not to other receptors 
commonly used by non-placental iRBC [18]. CSA in turn is not exploited by other 
iRBCs. The PfEMP1 variant mediating binding to CSA is var2CSA [23]. Var2CSA is 
quite conserved even in isolates from geographically distinct areas. This could 
explain why antibodies against var2CSA can bind parasite isolates obtained from 
other regions than the antibodies [24].  
 Another ability of infected red blood cells is the binding to uninfected erythrocytes, 
called rosetting. It is thought that rosettes have a masking effect for the iRBC, as the 
iRBC is in the middle, and completely covered with RBCs so that no proteins 
(antibodies) or cells from the immune system can “see” or eliminate the pathogen. 
The proximity of RBCs to the bursting schizont might also be an advantage for the 
merozoites to more rapidly invade new cells. The aggregation of RBCs even 
enhances the negative effect of sequestration. Capillaries, which are already 
constricted by sequestered iRBCs, may be blocked completely by floating rosettes. 
This embolism-like obstruction of microcirculation also occurs in cerebral malaria 
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and is thought to be an underlying cause of coma [25]. It is thus not surprising that 
50% of all wild type isolates show rosetting in vitro [26] and the rosetting rate is 
much higher in isolates from cerebral malaria compared with mild cases [27, 28]. 
The host receptors involved in rosetting are the blood group antigens A and B, 
complement receptor 1 (CR1), CD36 and glucosaminoglycans (GAGs) [29]. It is 
noteworthy that all of these receptors are glycosylated, which seems to be crucial 
for interaction. Additional serum factors are necessary as bridging molecules [30]. 
Luginbühl et al. showed that albumin, factor D and anti-band3 IgG are sufficient to 
restore the rosetting phenotype as in complete serum [31]. 
Clumping of iRBCs is mediated via platelets and the involved receptor is CD36.  
However, not all CD36 binding isolates show this phenotype, thus indicating the 
involvement of other receptors. The reason for the parasites to clump is yet 
unknown but has been shown to be associated with severe disease [32].  
 
Association of host receptors with domains of PfEMP1 
The interaction of PfEMP1 with the large number of different host receptors requires 
a large number of binding domains in the parasite protein. For a number of 
receptors the binding sites are already mapped (see Figure 3). The binding to the 
host receptor ICAM1 is mediated by the DBL2β-C2 region [33]. The binding to 
ICAM-1 is associated with cerebral malaria [34].  
Another receptor which shows strong interaction with PfEMP1 is CD36. The CIDR 
domain is the interaction partner for this receptor [35, 36]. CD36 is not abundant in 
the brain. The receptor is responsible for sequestration in organs other than the 
brain. In contrary to ICAM1 expression, the receptor is not sensitive to IFNγ or TNFα 
(reviewed in [25]). 
The interaction with CSA, important for PAM, is mediated by DBL3γ [17, 37]. It 
seems that parasites expressing PfEMP1 variants binding to CSA are rare and only 
have evolutionary advantages in pregnant women. 
The DBL1α domain is exploited by CR1 for rosetting and by heparin sulfate for 
sequestration in the aorta [38, 39]. 
The binding of PfEMP1 to different host receptors is extensively reviewed in [25, 40, 
41]. 
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Figure 2. Schematic illustration of cytoadherence. 
The cartoon shows the cellular basis of impaired microcirculation in the post-
capillary venules due to sequestration of infected red blood cells and rosettes. The 
parasite induces the release of cytokines, which up-regulate receptors such as 
ICAM-1 necessary for endothelium binding (modified from [25]). 
 
Structural details of Plasmodium falciparum Erythrocyte Membrane Protein 1 
(PfEMP1) 
P. falciparum expresses the large protein PfEMP1, which is 200-350 kDa in size and 
is exported from the parasite to the erythrocyte surface. PfEMP1 is encoded by the 
var gene family and is highly divers. About 60 different var genes are present in a 
haploid parasite genome. Only one var gene is expressed at a time in a mutually 
exclusive manner (var regulation: see next section). The architecture of PfEMP1 is 
complex. It is a single-pass transmembrane protein. The extracellular part 
protruding from the erythrocyte membrane into the host’s blood plasma is very 
variable. It is built from different blocks: the N-terminal segment (NTS), the Duffy 
binding like domain (DBL), the cysteine rich inter domain region (CIDR) and the C2 
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domain (see Figure 3). The NTS domain is semi-conserved and is located at the very 
N-terminal end of PfEMP1. The DBL domain itself is classified into 5 sub classes 
indicated by a Greek letter (α-ε) [42], where DBL1-α represents the first domain after 
the NTS. The classification was done according to conserved sequence stretches 
and to conserved cysteins in the sequences (see Figure 4A). The CIDR consists of 
semi conserved stretches and is located between DBL domains and in special 
cases followed by a C2 domain. There are 3 different types of CIDR domains (α-γ) 
(see Figure 4B). The intracellular part, the acidic terminal sequence (ATS), is rather 
conserved and may function as an anchor by interaction with RBC skeleton proteins 
and additional parasite proteins such as KAHRP and PfEMP3 [43, 44].  
 
 
Figure 3. Illustration of PfEMP1 domain structure. 
(a) A small PfEMP1 protein is shown consisting of the minimal arrangement i.e. the 
NTS domain, the DBL-CIDR tandem repeat and the ATS domain. In (b) a larger 
variant is shown. Here the C2 domain and higher order DBL domains are also 
included. The host cell receptors involved in binding at the respective domains are 
indicated (Figure from [41]). 
 
 
 
 
 
 
 22 
 
 
 
Figure 4A. Alignment and classification of DBL domains. 
DBL domains have been grouped according to their conserved regions (capital letter 
A-J) and their conserved cysteins (arabic numbers 1-10). Variable domains are 
indicated with dots and lines (roman numbers). Capital letters in the sequence 
indicate amino acids, small letters amino acid types: c (charged: D, E, H, K, R), + 
(positive: H, K, R), h (hydrophobic: A, C, F, I, L, M, V, W, Y), p (polar: C, D, E, H, K, 
N, Q, R, S, T), s (small: A, C, D, G, N, P, S, T, V), u (tiny: A, G, S), b (big: E, K, R, I, L, 
N, S, Y, W) (Figure from [42]) 
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Figure 4B. Alignment and classification of CIDR domains. 
CIDR domains classified according to semi conserved regions. Backslash indicates 
gaps in the sequence alignment. The amino acid code is the same as in Figure 4A 
(Figure from [42]) 
 
 
Knobs on the host cell surface 
The insertion of PfEMP1 on the RBC surface is not evenly distributed but instead 
packed into electron dens structures called knobs (Figure 5). These knobs are 
disributed over the surface of an infected RBC and visible by electron microscopy 
(see Figure 6) [45, Figure 6]. The knobs are the contact points in cell-cell interaction 
[25, 46]. Knob-less parasites are unable to adhere to endothelial cells under flow 
conditions [44]. Numerous parasite proteins are assembled in the inner face of the 
knobs including the knob associated histidine-rich protein (KAHRP) and PfEMP3 
[47]. It is thought that these proteins built up the knobs as it has been shown that 
KAHRP knock out parasites are knobless [43, 44] and anchor PfEMP1 in the RBC. It 
has been shown that the ATS domain binds to spectrin, actin and KAHRP [48]. 
KAHRP in turn also binds to spectrin [49]. 
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Figure 5. Schematic representation of a knob structure. 
The cartoon shows the structure of a knob. The thick red line represents the 
erythrocyte plasma membrane. PfEMP1 is inserted in the membrane and anchored 
probably via PfEMP3 (yellow oval) and KAHRP (in green) and attached to the 
cytoskeleton at spectrin/actin junctions. The whole knob structure may contain 
additional proteins; this is indicated with the big green circle (knob structure). 
 
 
Figure 6. Electromicrograph images showing knobs on an infected erythrocyte. 
Depicted are two erythrocytes where the backmost cell is uninfected and has a 
smooth surface, and the infected cell in front shows the knobby surface.  
(Figure adapted from http://www.scidev.net/scidev_images/black-and-white.jpg) 
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Regulation of var gene expression 
PfEMP1 is encoded by the var multigene family. This gene family consists of 
approximately 60 genes per haploid genome but with an almost unlimited repertoire. 
Almost 70% of all var genes locate close to the telomeres at the end of the 
chromosomes, the rest is found near the centromers in the middle of the 
chromosome [50]. The var genes at the telomers are normally arranged in a tail-to-
tail orientation, whereas the central vars are tandem repeats and thus show a head-
to-tail arrangement. The direction of transcription and the location on the 
chromosome can be predicted by their 5` non-coding sequence [51]. The upstream 
sequences (Ups) are arranged in four groups UpsA, UpsB, UpsC and UpsE [52]. 
UpsA and UpsE var genes are subtelomeric and transcribed towards the telomere in 
contrast to UpsB var genes, which are subtelomeric and transcribed towards the 
centromer. UpsB var genes are also present in the central region together with UpsC 
(see Figure 7). The role of the different upstream regions is not yet completely clear. 
Voss et al. found conserved sequence elements in the promoter of upsB and upsC 
var genes. The subtelomeric var promoter element (SPE) is unique for upsB var 
genes and the chromosome-central var gene promoter element (CPE) for upsC 
genes. It was also found that transcriptional regulation of var genes is dependent on 
their chromosomal location. Sub telomeric var genes are only expressed up to 18 
hours post infection whereas transcription of central var genes lasts 4-8 hours 
longer [53]. Expression of PfEMP1 from different chromosomal located var genes 
was also correlated with morbidity. There is evidence that UpsA and UpsB var-gene 
expression (sub telomeric) is associated with severe disease in children in Tanzania 
[54] but this has only been proven for UpsB in samples from Papua new guinea PNG 
[55]. 
The regulation of var-gene expression is very complex. var genes are expressed in a 
mutually exclusive manner, with only one gene being expressed by an individual 
parasite at a given time [56]. This mechanism of antigenic variation helps the 
parasite to escape from the host’s immune system. The switch from one var gene to 
another must be fast enough to evade the adaptation of the immune system but 
also as slow as possible to not exhaust the repertoire of var genes before being 
transmitted. P.falciparum does not undergo DNA rearrangement or gene conversion 
into an active expression site [57]. Transcription activation is restricted to a special 
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location in the nucleus and controlled by transcription initiation [56, 58, 59]. The 
mutual exclusive expression is not based on a negative feedback loop (e.g. PfEMP1) 
but on the non-coding information in the 5` region [60]. This means that not the 
presence of the protein itself regulates the transcription, but factors including 
untranslated DNA sequences upstream of the translational start point. This was also 
proven by Voss et al. [51] by transfection of plasmids with a 5` region of a var-gene 
followed by a drug resistance gene. Upon drug pressure the parasites expressed 
the resistance gene under the control of the var promoter. These parasites did not 
express PfEMP1 anymore; hence, the artificial promoter was filling the only 
transcription place for var genes. Proteins and transcription factors involved in this 
unique regulatory system are currently under investigation.  
 
Figure 7. Chromosomal organisation of var genes. 
The orientation of var genes at different locations within a chromosome are 
depicted. The black dot on the left is the telomere followed by the telomere 
associated repeat clusters (TARE). In green and in purple the subtelomeric var genes 
are shown and in yellow the central var genes are shown (Figure from [61]) 
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Aims of this thesis 
 
Improve recombinant protein expression of plamodial peptides in E.coli 
 
Heterologous expression of proteins is a commonly used technique to produce 
antigens for molecular biological examinations. There are more and more 
heterologous expression systems available like yeast, mammalian cells, insect cells, 
or even Dictyostelium discoideum but the most widely used system is still 
Escherichia coli. For protein expression in E.coli a large number of cell lines and 
expression vectors are readily available. The transfection and cultivation of E.coli is 
simple, fast and cheap. Problems can arise when conformation and modification of 
recombinant proteins are important, because E.coli is a prokaryote and has different 
folding and modification patterns than eukaryotes. Misfolding can also lead to 
solubility problems and to increased toxicity for the bacteria, resulting in low 
expression levels. Recombinant expression of plasmodial proteins brings along 
additional problems, as the genome of P.falciparum has an AT content of over 80% 
and that of E.coli has about 50%. The translation machinery of E.coli uses other 
triplets to code for amino acids as Plasmodium. As codons used by Plasmodium are 
rare in E.coli there are bacterial cell lines containing additional plasmids coding for 
those rare tRNAs. 
In my PhD I wanted to express differently sized fragments of PfEMP1 in E.coli. I 
tested various vector systems as well as different cell lines and cultivation media. 
The expressed proteins have been used as antigens for serological studies and as 
antigens for the induction of antibodies in mice.  
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Screen for morbidity associated antigenic regions in PfEMP1 
 
Clinical immunity against falciparum malaria is conferred by a repertoire of 
antibodies. It is believed that the major protective effect is directed against infected 
erythrocytes and thus against PfEMP1. This repertoire is acquired during childhood 
with repeated episodes of malaria. These episodes can be numerous and severe in 
young children but once the critical period of the incomplete antibody repertoire is 
overcome, the individual is mostly protected from clinical symptoms. However the 
number of infections needed to establish a protecting patchwork of antibodies 
seems to be small compared to the endlessness of possible surface antigen 
variants. That implies that it is not necessary to “see” all possible isoforms of 
PfEMP1 to build up immunological protection. There is evidence that there is a 
relative small subset of variants, which are more virulent but also more frequent than 
others and after contact with these types the individual is partially protected. 
In my PhD I was aiming to identify these variant PfEMP1 domains responsible for 
pathology and severe disease. I used two different approaches to study differential 
recognition of sera from children with an incomplete antibody repertoire and sera 
from clinically immune adults. Firstly, I aimed to clone and express large fragments 
(above 1000 amino acids) of the 3d7 parasite line in E.coli. Recognition frequencies 
of these recombinant proteins should be recorded and compared between non-
immune (incomplete) and immune (complete) sera in order to find differentially 
recognized variants. In the second approach I aimed to generate a random cDNA 
E.coli expression library. To ensure the expression of PfEMP1 fragments only, 
selected full-length var mRNA was used as starting material for cDNA synthesis. The 
rational was that with this approach not only the N-terminal part of the large PfEMP1 
protein could be tested but any individually random fragment from anywhere in the 
protein, not restricted to boarders of domains. It was planned to detect any 
differential recognition directly on comparative colony plots of this library. 
In addition to the random approach, we focused on DBL domains from different field 
isolates. DBLα domains are the most N-terminal domains in PfEMP1 and are 
present in most variants. DBLs have conserved sequence stretches intermitted by 
highly polymorphic regions and are known to bind to CR1, blood group antigen A 
and heparin. The association of the DBL variant with disease is not yet completely 
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clear. However, Kirchgatter et al. correlated DBLs containing 2 cysteins (in a certain 
position) with severe disease [62].  
We wanted to test for differences in recognition of DBL domains expressed in 
severe case malaria and in asymptomatic infections. First, we had isolated parasite 
RNA from malaria cases with different clinical manifestation. DBL domains from 
these cases were also sequenced. Sequence alignment showed no evidence of 
clustering of DBL sequences which would have revealed an association with certain 
clinical groups. As sequence differences were not obvious, we searched for 
differential recognition of recombinant DBL domains derived from severe cases or 
asymptomatic cases. We used adult sera from a cross sectional study and children 
sera from a longitudinal follow up study over 6 months with monthly intervals. We 
used samples from baseline and month 6. We wanted to test our hypothesis that 
DBL domains from severe cases are more frequently recognized in semi immune 
adults than DBL domains coming from asymptomatic patients. In the longitudinal 
study we were interested in the dynamics of recognition of DBL domains at baseline 
compared to samples from month 6. 
 
 
Development of pan specific anti-PfEMP1 antibodies  
Work on PfEMP1 is extremely hampered by the lack of specific non cross-reactive 
antibodies. Most of the available antibodies have strong cross-reactivity with human 
spectrin subunits, which can have a similar size as PfEMP1. Thus it was another aim 
of my thesis to generate pan-specific antibodies against PfEMP1 in mice, that are 
not cross-react with human proteins. We used different domains from various 
PfEMP1 molecules to strive our aims. We selected the NTS and the ATS domain of 
strain FCR3 S1.2 to be recombinantly expressed. Furthermore, we designed and 
tested synthetic peptides (with modifications) from conserved regions in the ATS 
domain as antigens.  
The lack of antibodies also delayed ongoing work in the analysis of the molecular 
interaction mechanisms in the formation of rosettes.  
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Chapter 2:  
Objectives of this thesis 
 
 
Objectives of this thesis are: 
 
1 To optimize recombinant protein expression of plasmodial proteins in E.coli.  
2 To screen for relevant antigenic regions in PfEMP1 influencing morbidity. 
3 To generate mouse polyclonal antiserum against PfEMP1. 
4 To perform localization studies on PfEMP1. 
5 To identify the cleaved fragment in rosetting and the role of PfEMP1. 
6 To assess recognition frequencies of DBL domains in different sera. 
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Chapter 3:  
 
Protein expression and characterization of different  
mouse antisera 
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Introduction 
 
Basic cell biology of Plasmodium falciparum 
Invading merozoites adhere to the erythrocyte surface and reorient themselves so 
that the apical end points to the erythrocyte membrane [63]. During invasion the 
rhoptries, the dense granules and the micronemes release their contents, which 
mediates the invagination by tight junction formation [64] and red cell cytoskeleton 
disruption by proteases [65]. The invasion event encloses the merozoite in a 
parasitophorous vacuole (PV) delineated by a parasitophorous vacuolar membrane 
(PVM) which consist of host and parasite derived material [66] and persists during 
the complete intra-erythrocytic development. The parasitophorous vacuolar 
membrane is the interface and thus important interaction site between the parasite 
and the host. Within the PV the parasite develops from the small ring stage to the 
larger trophozoite stage and the host cell is considerably modified. The parasite 
feeds on haemoglobin and deposits its waste products (haemozoin) in the food 
vacuole. Additionally, new parasite derived membraneous structures form in the 
erythrocyte cytosol in close proximity to the host cell membrane. These organelles 
are called Maurer’s clefts (as reviewed in [67]). Furthermore, the surface of the host 
cell membrane is extensively modified by insertion of parasite derived proteins and 
formation of protrusions visible by EM (electron microscopy). These protrusions are 
called knobs (see Figure 1) and it has been shown that PfEMP1 (Plasmodium 
falciparum erythrocyte protein 1) is anchored in these knobs and thus knobs are 
important for cytoadherence [44]. The protein essential for knob formation is the 
knob associated histidine-rich protein (KAHRP) [43, 44].  
As the parasite matures, the food vacuole with the haemozoin becomes visible in 
light microscopy. Visible brownish crystals consist of ferriprotoporphyrin dimers and 
are coloqually termed “malaria pigment”. After the transition from trophozoite to 
schizont the parasite takes up the complete space in the red blood cell, the 
Maurer’s clefts are pushed against the RBC membrane and grape like 
compartments become visible, which are the merozoites. The erythrocyte bursts 
and releases the merozoites.  
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For the remarkable restructuring of the host cell, the parasite has to transport 
proteins beyond its confines. This is a complex and not yet fully understood 
process, which will be discussed below. 
 
 
Figure 1. Schematic representation of an infected red blood cell. 
The cartoon shows a simplified picture of a cross section of an infected erythrocyte. 
The parasite (P) contains the nucleus (N) and the food vacuole (FV) and is 
surrounded by the parasitophorous vacuole (PV). Beyond the parasitophorous 
vacuolar membrane (PVM) the Maurer’s clefts (MC) are visible in the erythrocyte (E) 
cytosol. The protrusions on the erythrocyte surface are the knobs (K). 
 
Protein trafficking in Plasmodium falciparum 
During the asexual life cycle P. falciparum resides within a parasitophorous vacuole 
within the erythrocyte. Living in that special cell type implies advantages as well as 
disadvantages. The biggest benefit for the parasite is the protection from the host’s 
immune system. The red blood cell contains no nucleus and protein synthesis 
machinery anymore and thus is not able to present antigens of an intracellular 
parasite on the surface via MHC I. The intracellular parasite remains invisible to 
cytotoxic T-cells. However, an infected erythrocyte looses its flexibility and is more 
 36 
rigid. This and modifications of the RBCs surface lead to clearance by the spleen 
[68]. The parasite has to trade off some of its shelter to prevent spleen passage by 
cytoadherence. The iRBC adheres to the endothelial cells of the blood vessel by 
interaction between host cell receptors and the parasite protein PfEMP1. The 
integration of PfEMP1 into the RBC membrane is a complex procedure and leads 
directly to the negative aspects of living in a denucleated cell: the parasite has to 
build up completely new protein transport machinery.  
This new transport machinery has to fulfill complex tasks. As the parasite resides in 
a parasitophorous vacuole, proteins targeted to the red cell plasma membrane must 
not only be transported through the parasites membrane but also through the PVM. 
Despite the discovery of the export signal sequences (the export element, PEXEL 
[69], or the vacuolar transportation signal VTS [70]), the mechanisms of this 
transport remain to be elucidated [71]. These signals consist of a short hydrophobic 
part in the very N terminal part followed by differently charged amino acids like 
+xφx- i.e. RxLxE. To complicate a researchers life, there are some proteins 
transported beyond the confines of the PVM without carrying one of the mentioned 
signal sequences, among those is MAHRP1 (membrane associated histidine-rich 
protein 1) [45] and PfEMP1 [71]. Parasite derived organelles which may play a role in 
protein transport are the Maurer’s clefts (MCs). These vesicle-like membranous 
structures are located under the erythrocytes membrane. Many of the exported 
proteins are located at the MC either transiently like PfEMP1 and the knob 
associated histidine-rich protein (KAHRP) [47] or terminally like MAHRP1 [45, 72] or 
the skeleton binding protein 1 (SBP1) [73]. The latter one seems to be important for 
the transport of PfEMP1 from the MC to the erythrocyte surface. In a SBP1 
knockout strain the PfEMP1 transport is arrested at the MC [74], however in another 
study the point of arrest seems to be the PVM [75]. 
The transport of PfEMP1 to the red cell surface includes different trafficking 
intermediates. It is described that PfEMP1 is transported as soluble protein from the 
ER through the PM and PVM and then gets increasingly insoluble on its way to the 
MC clefts. It is inserted in the MC membrane with the C-terminal domain facing the 
erythrocyte cytoplasm. Here it complexes with KAHRP and is then transported to 
the erythrocyte membrane [76]. 
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Since no specific and non-cross reactive antibody against PfEMP1 exists, we tried 
to generate good pan specific anti-PfEMP1 antibodies to further perform localization 
and trafficking studies on the major virulence factor PfEMP1. 
 
Mechanisms of rosetting of Plasmodium falciparum 
The spontaneous binding of uninfected red blood cells to iRBC is called rosetting. 
Rosetting is associated with severe malaria and in Africa especially with cerebral 
malaria [27, 28]. In Papua New Guinea PNG no correlation of rosetting and severe 
disease was found [77] probably due to CR 1 receptor deficiency in 79% of the 
population [78].  The reason for the severe effects of rosetting is most likely the 
blocking of blood flow in the capillaries and the resulting oxygen lack in the tissue 
i.e. in the brain. Luginbühl et al. [31] showed that factors in the serum mediate 
rosette formation. Their work showed that after mechanical rosette disruption, 
rosetting of the culture strain FCR3 S1.2 could be completely restored by the 
addition of complement factor D, albumin and anti-band 3 NAbs (naturally occurring 
Antibodies). As the effect of these proteins is additive compared to the incubation 
with only one, it seems that there are different interaction partners on the iRBC and 
the RBC. The complement factor D is a serine protease and it was investigated if 
proteolytic effects are necessary for rosetting. It was very surprising that there was a 
65kDa fragment cleaved from the iRBC surface since the only known substrate for 
factor D was factor B. However, the fragment has not yet been identified and 
remains to be elucidated from which parasite protein this peptide was cleaved off.  
 
In order to identify potential candidates cleaved by factor D we aimed to generate 
anti-PfEMP1 antibodies to further investigate if the processed protein is PfEMP1. 
 
Recombinant protein expression of plasmodial proteins 
For the generation of antibodies it is crucial to express the antigen in reasonable 
large amounts and as pure as possible. We chose E.coli as a heterologous 
expression system for the expression of different protein domains from PfEMP1. The 
difference of the two organisms Plasmodium and E.coli implies problems in protein 
expression. This typically results in lack of expression or in insoluble inclusion 
bodies [79]. In some cases hundreds of different refolding buffers had to be tested 
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to obtain a soluble protein from inclusion bodies [80]. Reasons for these expression 
problems are the high AT content of 80% in Plasmodium DNA and the resulting 
different codon usage compared to E.coli. Additionally, genes are often larger (50%) 
than their homologous in i.e. yeast [81] and possess long disordered regions [82]. 
The translational start sites of plasmodial proteins are also sometimes cryptic 
resulting in multiple truncated products in E.coli [83]. Because all these difficulties, 
the group of Mehlin et al. [83] cloned 1000 open reading frames to find a universal 
rule to predict the expressability and the solubility of proteins from P.falciparum 
expressed in E.coli. However, they concluded that there were no such general 
result, but they could align physical features of the protein with expression 
problems. Only 30% of all clones expressed a protein and only 63 were soluble. 
Increasing molecular weight, increasing pI (isoelectric point), greater protein disorder 
and lack of E.coli homology were all highly and individually correlated with 
expression problems. It was also reported that induction of an expression culture at 
post-log phase is advantageous compared to the usual induction at mid-log [79]. 
 
In this study we attempt to clone and recombinantly express protein domains of 
PfEMP1 for subsequent serological studies. We attempted to generate a random 
E.coli expression library for PfEMP1 fragments. Furthermore, we generated 
polyclonal mouse sera against different domains of PfEMP1.  
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Chapter3 
Materials and methods 
 
In vitro cultivation of Plasmodium falciparum 
Plasmodium falciparum strain 3D7 was cultivated in RPMI 1640 medium 
supplemented with 25mM HEPES, 0.5% Albumax II, 50mg/l hypoxanthine, 0.25% 
sodium bicarbonate, 10µg/ml neomycin sulphate and 0+ red blood cells at 5% 
haematocrit. Cultures were incubated at 37°C in an atmosphere of 3% oxygen, 4% 
carbon dioxide and 93% nitrogen as described previously [84]. 
Plasmodium falciparum strain FCR3 S1.2 was cultivated with 10% human AB+ 
serum instead of Albumax II. 
Parasites were synchronized by 5% sorbitol treatment as described by Lambros 
and Vanderberg [85]. 
 
Enrichment of late stage parasites using a magnetic cell sorter 
A MACS CS Column (Miltenyi Biotec) was assembled in the magnetic cell separator 
VarioMACS (Miltenyi Biotec) and flushed with 60ml of PBS according to the 
manufacturers protocol. A 22G hypodermic needle was used as flow resistor 
resulting in a flow rate of 3ml/min. 10 to 50ml resuspended late stage Plasmodium 
culture was run through the column. The column was washed with 3 culture 
volumes PBS. The flow through was discarded. The column was removed from the 
magnetic field, the flow resistor was removed from the column and the retained 
iRBCs were eluted from the steel wool by flushing with 50ml PBS. Eluted parasites 
were centrifuged at 4000g at 4°C for 10 min. The supernatant was discarded and 
the parasites stored at -20°C until use. 
 
Plasmodium falciparum protein extraction 
Saponin lysis 
10ml of a Plasmodium culture with a parasitaemia of 3-7% were harvested by 
centrifugation at 1000g for 5 minutes at room temperature. Ice-cold PBS containing 
0.05% saponin was added to the pellet and incubated on ice for 5 minutes. The 
lysed culture was centrifuged at 4000g for 10 min at 4°C and subsequently washed 
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with PBS until the supernatant was clear. The washed pellet was stored at -20°C 
until use. 
 
Triton X-100 extraction 
10ml of a Plasmodium culture with a parasitaemia of 3-7% was harvested by 
centrifugation at 1000g for 5 minutes at room temperature. 5ml ice-cold PBS 
containing 1% Triton X-100 and a protease inhibitor cocktail (Complete®, Roche) 
were added to the pellet and incubated on ice for 5 minutes. The lysed culture was 
centrifuged at 4000g for 10 min at 4°C and the pellet subsequently washed with 
PBS. The pellet was resuspended in PBS containing 2% SDS and centrifuged for 10 
minutes at 15000g. The supernatant containing the Triton X-100 insoluble and SDS 
soluble protein fraction (integral membrane proteins) was stored at -20°C until use.  
 
Genomic DNA isolation of Plasmodium falciparum 
Saponin lysed parasite pellets were resuspended in 600µl TE buffer (10mM Tris, 
1mM EDTA, pH 7,4). Parasites were disrupted by adding 18µl 20% SDS (final conc.: 
0,6%) and 6µl 20mg/ml Proteinase K (final conc.: 200µg/ml) and incubated at 60°C 
over night. The DNA was extracted twice with 2 volumes of a 1:1 mixture of aqua-
phenol:chloroform followed by an additional extraction with chloroform only. The 
aqueous phase was precipitated with 0.3M NaAcetat pH 5.2 and 2.5 volumes 100% 
ethanol at -20°C. 
 
Plasmodial RNA extraction and complete cDNA synthesis 
The pellet from synchronized parasites (minimum 5% parasites in late ring stage) 
was resuspended in 5 volumes Trizol® (Invitrogen). The RNA was extracted from the 
lysate with 0.2ml chloroform per ml Trizol® and precipitated with 3 volumes of 
isopropanol. To improve purity the pellet was again resuspended in Trizol® (0.5 
original volumes), extracted with chloroform and then precipitated. The precipitated 
DNA was digested by two subsequent incubations with RQ1 RNAse free DNAse 
(Promega) according to the manufacturers protocol in the presence of RNAse 
inhibitors. After each DNAse digest the RNA was extracted and precipitated as 
described above. As gDNA is a notorious contaminant in RNA extractions, a control 
PCR was introduced prior to cDNA synthesis. The control PCR contained 1µl from 
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the RNA preparation as template and degenerated dbl1α_fwd and dbl1α_reverse 
primers. These primers amplify most DBL domains from Plasmodium falciparum 
(personal communication M. Kaestli). A positive PCR control was also included. 
After initial denaturation (5 min 96°C) the PCR cycle was as follows: 30 seconds 
annealing at 52°C, 45 seconds elongation at 72°C and 45 seconds melting at 94°C, 
25 cycles. If PCR (visualized by gel electrophoresis) resulted negative, the extracted 
RNA was considered suitable for cDNA synthesis. 
cDNA synthesis was performed using either Sensiscript® or M-MuLV reverse 
transcriptase with random hexamer primers, in accordance with the respective 
manufacturers protocol. RNA amounts used in a cDNA synthesis reaction varied 
from below 100ng to 1µg. A control reaction without reverse transcriptase was 
always included. 
 
General RNA reverse transcription  
RNA samples either from beads hybridisation or crude were mixed with 3.5µl 0.1M 
DTT, 2µl RNAse inhibitor, 7µl 10x RT-Buffer (Sensiscript/M-MuLV), 7µl 5mM dNTPs 
and RNAse free dH2O to 70µl. The reaction mix was split in a 50µl and a 20µl 
aliquot. To the 50µl aliquot 2µl of reverse transcriptase was added, the other was left 
without enzyme as negative control. Both tubes were incubated at 37°C for 90 min. 
After the reaction the RNA:DNA duplex was melted at 93°C for 3 min and the RNA 
was digested with 1µl of RNAse A (1mg/ml) at 37°C for 20 min. The resulting single 
strand cDNA was stored at -20°C. 
 
Full length var mRNA extraction 
To extract only the full-length var mRNA transcripts from a total RNA preparation a 
hybridization technique was used as described in the following: 1pmol of a 
biotinylated oligonucleotide complementary to the ATS domain was incubated 
together with the total RNA in hot (65°C) binding buffer (0.5M LiCl, 1mM EDTA, 
10mM Tris, pH7.5). After slow cooling from 65°C to 4°C over 30 minutes, 200µg of 
streptavidine coated magnetic beads (Dynal) were washed, dissolved in 5.5M LiCl 
and added to the RNA:DNA hybrid and incubated for 30 minutes at 37°C on an 
over-head shaker. Beads were collected on the wall of the reaction tube by a 
surrounding magnet and washed 3 times with wash buffer (10mM Tris, 1mM EDTA, 
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0.15M NaCl, pH 7.5). Reverse transcription was performed directly on the RNA 
hybridized to the beads as described previously (General RNA reverse transcription, 
Material and Methods Chapter3).  
 
cDNA amplification 
To amplify minute amounts of full-length cDNA a modified SMART® (Clontech) 
system was used. To start the synthesis, a modified SMART random primer was 
used. This primer contains a random part of 6 nucleotides followed by a known 
sequence that works as primer sequence in downstream experiments. The reaction 
also contains a SMARToligo, which has 6 guanidine residues on its 3` and a known 
sequence on the 5` end. At the 5` end of the RNA the reverse transcriptase includes 
several cytosine residues to the growing strand of the cDNA. The SMARToligo pairs 
with the extended cytosine rich cDNA tail and thus serves as a second template for 
the reverse transcriptase to switch to. The resulting first strand cDNA contains 
known sequences at both the 3` and the 5` end of the cDNA (see also Figure 1 for 
details). A PCR using the primer pair SMART_PCR_fwd and SMART_PCR_reverse 
amplified the cDNA.  
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Figure 1. Schematic representation of SMART cDNA amplification.  
(Source: www.clontech.com) 
 
 
Polymerase chain reaction (PCR) 
Regular PCR 
A standard PCR reaction mix consisted of the following: 2U Taq polymerase, PCR 
Buffer BD (Solis Biodyne) containing 80mM Tris pH 9.4, 20mM (NH4)2SO4, 1.5mM 
MgCl2, primer final concentration each 10µM, final concentration of each 
deoxynucleotide 2µM, and 10ng template DNA. The reaction volume was 50µl. 
 
Long range PCR 
As template for long range PCR, high molecular weight genomic DNA was used at a 
final concentration of approximately 50ng. A special reaction buffer containing 
50mM Tris, 16mM ammonium sulfate, 2.5mM MgCl2 and 150µg/ml BSA was used to 
maintain a constant pH throughout a wide temperature range. As polymerase a 
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mixture of 2.5U regular Taq and 0.5U proofreading Pfu was used. Primer 
concentration was 10µM and the final reaction volume was 50µl. 
 
Agarose gel electrophoresis 
0.8 to 2% agarose was boiled in 0.5x TBE buffer and poured into a gel chamber. 
DNA samples were loaded in 1 x blue juice (30% glycerol, a tip of spatula 
bromphenol blue and xylene cyanol, 70% TE) and run at 100V constant current for 
1h and stained in ethidium bromide for visualization under a UV source. 
 
Restriction digests and ligation 
Restriction digests were performed in accordance with the manufacturers protocol 
using 10U of restriction enzyme in a final volume of 50µl. 
For the preparation of the ligation mix, the following calculation was applied: 
 
 (10ng vector x size of insert in kb x 10) / size of vector in kb = ng insert.  
 
The volumes of the insert and the vector were calculated according to their 
concentrations and mixed with 2µl ligation buffer and 1µl T4 ligase (Promega) to 
yield an end volume of 20µl.  The reaction was incubated at room temperature for 30 
minutes or over night at 16°C.  After ligation the mixture was chlorofom:phenol 
extracted and precipitated for maximum purity. 
 
Cloning of different expression constructs 
(see also Figure 2 for cloning strategies) 
 
Cloning of long range PCR products 
A large set of different primers was tested for long-range PCR conditions. They 
consisted of seven forward (F1-F7) and four reverse primers (R1-R4) (see appendix: 
primer sequences). The best result was achieved with primer pair F4 and R4. All 
primers contained restriction sites for SacI and NotI. PCR products were ligated into 
pHIS parallel1 for recobinant protein expression. 
(Figure 1A) 
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Random cloning of cDNA 
cDNA from either preparations of complete cDNA or of full length var mRNA was 
subcloned via TOPO cloning kit (Invitrogen) into pTrcHIS2 expression vector without 
restriction digest using the A-overhangs from the PCR reaction in accordance with 
the manufacturers protocol.  
(Figure 1A) 
 
Vector modifications of pTrcHis2  
A PCR product from the primer pair GST_fwd and MCS_reverse that contains the 
GST sequence as well as the multiple cloning site (MCS) of pGEX 4T1 was ligated 
into the pTrcHIS2 vector. A  “gene of interest” cloned into the MCS of the new 
vector pTrcHis2_GST has two purification tags: an N-terminal GST and a C-terminal 
6xHis.  
(Figure1B) 
 
Cloning of acidic terminal segment (ATS) of PfEMP1 
The ATS domain was amplified using the primer pair ATS_FCR_fwd and 
ATS_FCR_reverse, which contains the restriction sites EcoRI and NotI. Genomic 
DNA from the Plasmodium falciparum strain FCR3 S1.2 was used as template. PCR 
products were ligated into the pTrcHis2_GST vector, which was cut with the same 
enzymes as the PCR product.  
(Figure1B) 
 
Cloning of ATS N-terminal and C-terminal fragments 
The N-terminal part of the ATS was amplified from genomic DNA from the 
Plasmodium falciparum strain FCR3 S1.2 using primer pair ATS_FCR_2_fwd and 
ATS_FCR_nterm_reverse, that contain the restriction sites EcoNI and BglII. PCR 
products were cloned into the expression vector pQE-16. For the C-terminal part, 
the primer pair was ATS_FCR_cterm_fwd and ATS_FCR_2_reverse; the rest of the 
procedure was the same as for the N-terminal fragment. 
(Figure1C) 
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Cloning of NTS (N-Terminal Segment) of FCR3 S1.2 
The NTS domain was amplified using the primer pair NTS_FCR_fwd and 
NTS_FCR_reverse, which contains the restriction sites EcoRI and NotI. Genomic 
DNA from the Plasmodium falciparum strain FCR3 S1.2 was used as template and 
PCR products were ligated into the vector pTrcHis2_GST (Invitrogen). 
(Figure 1B) 
 
Preparation of electrocompetent cells and electroporation of E.coli 
An over-night culture from a single colony was diluted 1:20 in LB medium, grown to 
OD600= 0.8 harvested and washed 4 times in sterile ddH2O at 4 °C to remove 
residual salts. The bacterial pellet was aliquoted, snap frozen in liquid nitrogen and 
stored at -80°C. 
For transformation, 40µl of concentrated electrocompetent cells were mixed with 
plasmid DNA in a precooled electroporation cuvette (gap 0.2cm). Electroporation 
settings were 2500V and 5ms single-pulse. For reconstitution, the transformed 
bacteria were immediately transferred into warm LB medium without antibiotics for 
30 minutes. The suspension was spread on LB agar plates with the appropriate 
antibiotics and grown overnight at 37°C. 
 
Plasmid preparation and sequencing 
Plasmids were extracted from 2ml over-night culture with a MiniPrep kit (Qiagen). 
Plasmids were sequenced at Macrogen Inc. in South Korea. 
 
Recombinant protein expression in Escherichia coli 
Small-scale expression 
For over-night cultures, 4ml LB-medium supplemented with 100µg/ml ampicillin was 
inoculated with a single colony containing the expression plasmid and incubated at 
37°C, shaking at 220rpm. The overnight culture was diluted 1:100 in 5ml fresh LB-
medium containing antibiotics and was further incubated at 37°C. The protein 
expression was induced by the addition of 1mM IPTG when OD600 reached 0.8. 
Bacteria were harvested 4 hours later by centrifugation at 4°C, 8000g for 15min. 
Pellets were stored at -20°C until further use. 
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Medium and large-scale expression 
For medium and large-scale expression of recombinant protein, the volume of the 
expression culture was raised to 50 or 500ml. 
E. coli expression strains used were: BL21 for pGEX plasmids, M15 for pQE 
plasmids and TOP10 for pTrcHIS2 plasmids. The LB medium was supplemented 
with 100µg/ml Kanamycin for M15 cells and with 1% Glucose for TOP10 cells. 
 
E.coli cDNA library colony blots 
Transformed E.coli were spread on LB agar plates and grown over night at 37°C.  
The next day colonies were printed directly from the plate onto a round 
nitrocellulose membrane. The membrane was then duplicated and re-grown on 
fresh plates (facing colonies up). One membrane was stored at 4°C as master. The 
other was transferred to a new agar plate containing 1mM IPTG and grown for 
additional 4h at 37°C. The membrane was gassed in chlorofom vapor for 15 minutes 
before it was transferred into lysis buffer containing 100mM Tris pH7.8, 150mM 
NaCl, 5mM MgCl2, 15% BSA, 40µg/ml lysozym and 1µg/ml DNAse. Lysis was 
complete when no bacterial material was visible anymore, usually over-night. The 
membrane was developed similar to a Western blot, including blocking, primary and 
secondary antibody and stained with NBT/BCIP. Colonies that produced a 
recombinant protein left a black spot on the membrane. When the developed 
membrane was aligned with the master membrane positive clones were revealed 
and cultivated for further analysis (Sambrook and Russell, Molecular cloning, 3rd Ed, 
14.14 Protocol 2). 
 
Purification of 6xHIS tagged recombinant proteins 
Purification of NTS 
The bacterial pellet from the expression culture was thawed on ice. 5 pellet volumes 
of lysis buffer supplemented with 100µg/ml lysozyme and 1µg/ml DNAse were 
added and incubated for 30 minutes. The lysate was sonicated at 50% duty cycle 
with five, 10 seconds bursts with 10 seconds intervals in a microtip sonicator. 
Soluble proteins were separated from cellular debris by centrifugation at 10000g for 
30 minutes at 4°C. The supernatant was mixed with 0.5ml of Ni-TA-Agarose beads 
(Invitrogen) and incubated for 1h. The protein was further purified according to the 
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manufactures protocol (Qiagen, the expressionist). Eluted proteins were stored at     
-20°C. 
 
Purification of C-terminal ATS and N-terminal ATS  
For the insoluble proteins ATS C-term and ATS N-term, the pellet was lysed in 
inclusion body lysis buffer (2% Triton X-100) supplemented with 100µg/ml lysozyme 
and 10µg/ml DNAse. Sonication conditions were as indicated above. The insoluble 
proteins were harvested by centrifugation at 10`000g for 30 minutes. The 
supernatant was discarded and the pellet resuspended in inclusion body lysis 
buffer. This step was repeated 3 times. For the last resuspension of the insoluble 
pellet, PBS was used to avoid Triton X-100 in the further purification procedure. The 
washed pellet was resuspended in 8M Urea buffer and mixed with 0.5ml Ni-TA-
Agarose beads. The protein was further purified according to the manufactures 
protocol (Qiagen, the expressionist). Eluted proteins were stored at 4°C.  
 
Purification of GST tagged recombinant proteins 
The bacterial pellet was lysed as indicated in the “Purification of NTS” protocol. The 
supernatant was mixed with 0.5ml glutathione-sepharose 4B (Pharmacia) and 
incubated in an over-head shaker for 30 minutes at room temperature. The 
sepharose slurry was centrifuged, washed and eluted with 10mM reduced 
glutathione as described in the manufacturers protocol. Eluted proteins were stored 
at -20°C. 
 
SDS-PAGE and Western blot analysis 
Proteins were resuspended in Laemmli buffer, boiled for two minutes and separated 
on a 5 or 12% SDS polyacrylamide gel according to their size. Proteins were 
transferred to a nitrocellulose membrane (Hybond C, 0.45µm, GE Healthcare) in a 
semi-dry blotter. Tris-Glycine buffer containing 20% methanol was used as transfer 
medium. Membranes were blocked with TNT (Tris, NaCl, Tween-20 0.1%) 
containing 5% non-fat milk powder.  Primary and secondary antibody incubation 
was done in TNT containing 1% non-fat milk powder. Primary antibody dilutions for 
mouse anti-NTS and mouse anti-ATS1-4 were 1:200 – 1:1000 and for mouse anti-
6xHIS 1:5000. Membranes were incubated with the primary antibody for 2h on a 
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shaker at room temperature or over night at 4°C. Washing was performed with TNT 
3 times for 10 minutes. Secondary antibody dilutions used were: goat anti-mouse 
AP 1:10000 and goat anti-human HRP 1:5000. Both were incubated for 1 hour at 
room temperature. Secondary antibodies were visualized depending on the liked 
enzyme: for alkaline phosphatase alkaline Tris-buffer containing 300µg/ml BCIP and 
150µg/ml NBT was used and the color reaction was stopped with ddH2O; for 
horseradish peroxidase a enhanced chemoluminescence detection kit (GE 
Healthcare) was used and the filters exposed to Kodak XE films for 10 seconds to 
10 minutes. 
 
Immunization of mice 
Recombinant NTS 
Six NMRI female mice were immunized with purified recombinant NTS. 3 mice were 
subcutaneously immunized with 10µg recombinant protein and MPL-TDM (Sigma) 
as adjuvant and 3 mice with ImmuneEasy (Invitrogen) as adjuvant. The mice were 
boosted twice with the same antigen concentration after 3 and 5 weeks. 10 days 
after the last boost the mice were sacrificed and the sera stored at -20°C for further 
analysis. 
 
Synthetic peptides 
Four different peptides ATS1 to ATS4 (Alta-Bioscience) (see appendix for sequence 
information) all derived from conserved ATS regions of PfEMP1, were chosen for 
immunization. Two peptides were differently modified to enhance antigenicity. 
Peptide ATS1 was coupled to Keyhole limpet heamocyanin (KLH), peptide ATS2 
was synthesized as Multi-Antigenic-Peptide (MAP) in which 8 peptides are coupled 
to a branched lysine core. Peptide ATS3, being the longest peptide, was not 
modified. Peptide ATS4 was chosen for its predicted coiled-coil domain and also 
not modified to avoid interference with the self-assembling of its 3-dimensional 
structure. 
For mouse immunization a peptide solution was emulsified with TiterMax Gold® 
(Sigma) in a ratio of 1:1 containing 100µg antigen per injection. For each antigen 3 
NMRI mice were immunized once and titers were check 5 weeks later. Boosting was 
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not necessary and mice were sacrificed 6 weeks after immunization and the sera 
stored at -20°C for further analysis.  
 
Enzyme linked immuno adsorbed assay (ELISA) 
MaxiSorb (Nunc) 96 well ELISA plates were coated with 10µg/ml peptide or protein 
in PBS at 4°C over-night. Plates were washed in an ELISA-plate-washer once and 
blocked with 5% non-fat milk powder on PBS-T (PBS, 0.01% Tween-20) at room 
temperature for one hour. Plates were then washed again and incubated with mouse 
sera in serial dilutions starting at 1:100 in PBS-T with 1% non-fat milk powder at 
room temperature for 2 hours. Plates were washed twice and incubate for another 
hour with goat anti-mouse alkaline-phosphatase labeled antibodies (Sigma) at a 
dilution of 1:10000. The washed plate was developed with 1mg/ml PNP (p-
Nitrophenyl Phosphate) in alkaline buffer and measured in an ELISA reader at a 
wavelength of 405nm one to three hours later. 
 
Immuno fluorescence assay (IFA) 
Mixed-stage parasite cultures with at least 8% parasitaemia were thinly smeared on 
a microscopic glass slide. Cells were fixed in ice-cold acetone:methanol (1:1) for 5 
minutes. The slides were blocked with sterile-filtered 5% BSA in PBS for one hour at 
room temperature in a humid chamber. Cells were washed and incubated with 
mouse sera in PBS-T with 1% BSA for 2 hours. Slides were washed again and 
incubated with goat anti-mouse Cy3 labeled antibodies for one hour. IFA slides were 
washed, dried and mounted in anti-fade solution containing DAPI (1µg/ml) for 
visualization of the nuclei.  
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Figure 2. Vector maps of cloned expression constructs. 
In A vectors and enzymes are depicted for cloning of long-range PCR and amplified 
cDNA cloning. In B the modification of the TOPO pTrcHIS2 vector with the GST 
expression cassette from pGEX 4T1 is shown. The new vector pTrcHIs2_GST was 
used for cloning of ATS and NTS domains. In C the cloning of ATS N- and C- 
terminal fragments is indicated. 
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Chapter 3 
Results 
 
To dissect the immuno-protective role of different domains in PfEMP1, we 
attempted to generate a set of recombinant proteins against which we wanted to 
test sera from patients with different clinical history or age. Furthermore, we planed 
to generate specific antibodies against different domains in PfEMP1.  
We chose classical molecular biological methods to tackle our aims. We attempted 
expression of long PfEMP1 fragments from a random cDNA library, from full lengths 
ATS and from full length NTS domains. We investigated immunization with 
recombinant NTS and synthetic peptides of the ATS domain. These multiple 
approaches and corresponding results are described in the following. 
 
1. Long range PCR, cloning and expression 
To obtain large PfEMP1 PCR fragments for recombinant protein expression, a set of 
seven forward primers (F1-7) and four reverse primers (R1-4) were designed based 
on the P. falciparum 3d7 genome sequence (primer sequences listed in “Primers & 
Peptides”). The fragments reached from the NTS domain to the DBLγ domain and 
sized from 3 to 5 kb, depending on the domain structure of the var gene. Each 
forward primer was tested with each reverse primer and results are shown in Figure 
1. To assess the limits of the long-range PCR (l-rPCR), an ATS reverse primer was 
also included. It was possible to amplify a small full-length var gene with a size of 
about 7kb (see Figure 1, Lane 10). As the primer sequences were chosen on 
relatively conserved DNA stretches each primer can anneal to a subset of var genes.  
Various fragments were prepared for cloning into an expression vector, however the 
3.8 kb fragment amplified with primer pair F4/R4 had the highest yield (Figure 1, lane 
14) and was the only one, which was successfully cloned for protein expression in 
pHIS paralell1 (see Figure 2). Upon protein induction however, no recombinant 
protein expression was detectable neither in Coomassie blue stained 
polyacrylamide gels (Figure 3) nor in Western blots (data not shown). Alterations in 
temperature, induction time, different bacterial strains (M15, Bl21, Origami) or rich 
expression media did not improve protein expression conditions.  
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Figure1. Testing different primer combinations for PfEMP1 long-range PCR.  
PCR products of different primer combinations (see Table 1) were tested. 5 
microliters of a 50 µl PCR reaction were loaded on a 0.7% agarose gel in lanes 1-30. 
M1, 1kb ladder; M2, lambda HindIII ladder.  
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Lane 5` primer 3` primer Lane 5` primer 3` primer 
1 F2 R1 16 F5 R1 
2 F2 R2 17 F5 R2 
3 F2 R3 18 F5 R3 
4 F2 R4 19 F5 R4 
5 F2 ATS 20 F5 ATS 
6 F3 R1 21 F6 R1 
7 F3 R2 22 F6 R2 
8 F3 R3 23 F6 R3 
9 F3 R4 24 F6 R4 
10 F3 ATS 25 F6 ATS 
11 F4 R1 26 F7 R1 
12 F4 R2 27 F7 R2 
13 F4 R3 28 F7 R3 
14 F4 R4 29 F7 R4 
15 F4 ATS 30 F7 ATS 
 
Table 1. Different primer pair combinations applied for long-range PCR 
amplification of PfEMP1. 
The table shows all possible permutations of forward primers F2-F7 and reverse 
primers R1-R4 and reverse-ATS with its corresponding lane in figure 1. Primer F1 
did not work and was excluded. Primer pair F4/R4 in grey was used for downstream 
experiments (for sequence information see: “Primers & Peptides”). 
 
Figure 2. Control digest of cloned l-rPCR.. 
Restriction enzyme digests of plasmid preparation 
of pHIS1_F4/R4. Lane 1 undigested plasmid, lane 2 
and 3 plasmid digested with either SacI or NotI, lane 
4 plasmid digest with both enzymes. The F4/R4 
fragment is visible at 3800 bp, the backbone at 
5500 bp. M, 1kb marker. 
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Figure 3. Small-scale expression of PCR product F4/R4 in pHIS parallel1. 
Total protein extracts of induced(+) and noninduced(-) bacterial cultures harboring 
plasmid pHISparalell1_fragF4/R4 were separated on a 12,5% acrylamide gel stained 
with Coomassie blue. 
Three different expression clones were tested: clone 1 (lane 1 and 2), clone 2 (lane 3 
and 4), clone 3 (lane 5 and 6). Arrowhead is positioned at expected size of 
recombinant protein (135 kDa). M, Marker SeeAllBlue (Invitrogen). 
 
2. Random cDNA cloning and protein expression 
With the aim of testing the serological effect of different domains of PfEMP1, we 
performed a random cloning approach. Total RNA was isolated from Plasmodium 
falciparum 3d7 and FCR3 S1.2 culture strains (see Figure 4A). The total RNA was 
reverse transcribed with random primers and the resulting cDNA was cloned into 
TOPO pTrcHIS2 plasmids for random expression. Sequencing analyses of these 
clones revealed that only rRNA had been reverse transcribed and thus is present as 
inserts in TOPO pTrcHIS2. There was no clone containing a reverse transcription 
product derived from an mRNA fragment. Therefore, a different approach was 
chosen to enrich for full-length var mRNA from the crude RNA preparation (see 
materials and methods “var mRNA extraction”). The isolated mRNA was transcribed 
into cDNA. Due to its low concentration, it was not possible to clone the cDNA 
obtained after mRNA purification.  
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Therefore an amplification cDNA step was added using the modified SMART® 
method (see Figure 4B). Although the amplification was successful the cloning of the 
amplified cDNA again only showed rRNA and tRNA. Neither an annotated mRNA 
fragment nor a var transcript was ever found in the cloned fragments. 
 
Figure 4. RNA preparation and SMART cDNA amplification. 
A. RNA extractions from two different Plasmodium falciparum strains were 
separated on a non reducing agarose gel. The ribosomal RNA is visible as very 
strong bands at 1,6kb and 2,9kb. Lane 1: 3d7; lane 2+3 FCR3 S1.2. B. Agarose gel 
with two SMART cDNA amplification products from 3D7 (lane 4) and FCR3 S1.2 
(lane 5). The dominant transcript length is around 1kb as indicated by the 
arrowhead.  
 
3. Establishing the colony blot method for ATS expression from Plasmodium 
falciparum 
The colony blot system was originally designed to find expressing and serological 
relevant clones in a complex cDNA library. As the cDNA library was notoriously 
contaminated with transcripts of rRNA, an expressing clone was never found. But 
when used as tool to screen for an expressing colony after cloning a specific PCR 
product amplified from genomic DNA, this problem should not occur. We 
successfully applied the method for screening for an expression clone of the 
complete FCR3 S1.2 ATS domain (see Figure 5A). Positive clones were picked from 
the master plate and analyzed by PCR, where 80% proofed to have a correct insert. 
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As depicted in Figure 5C, Western blots of small-scale expression cultures revealed 
a week expression of full length GST-ATS-HIS at 90 kDa, however the expected size 
was 72 kDa. Unfortunately, purification of the recombinant protein over a Ni-TA-
column did not enable sufficient purity (Figure 5B). Purification using Glutathione-
Sepharose was not possible, because the expressed protein was not soluble. 
Because of the unsatisfactory purity, the wrong size and the low expression level the 
protein was not used for further immunization of mice. 
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Figure 5. Colony blot and expression of ATS in pTrcHIS2_GST. 
A. Colony blot with ATS-6xHIS expressing clones (dark black spots). The blot was 
probed with anti-6xHIS antibodies. B. Coomassie blue SDS page with purified 
recombinant ATS. C. Western blot of recombinant ATS probed with anti-6xHIS 
antibody. 
 
 
 
 
 
 
100kDa 
 
250kDa
a 
 
150kDa 
 
75kD
a 
 
 50kDa 
 
 
37kD
a 
 25kD
a 
 
 
20kD
a 
 
 15kD
a 
 
 
250kDa 
 150kDa 
100kDa 
 75kDa 
 
50kDa 
 
 37kDa 
 
25kDa 
20kDa 
 
 
A 
B C 
 60 
4. Cloning and expression of the NTS of strain FCR3 S1.2 
For performing localization studies and Western blots we generated a set of 
polyclonal mouse sera. Because immunization with recombinant ATS was not 
possible due to unsatisfying yield and purity, we decided to use the NTS domain 
instead. For this, the smaller NTS domain was cloned into the same expression 
vector as the ATS domain. The expressed recombinant protein has an expected size 
of 33.6 kDa and an apparent size of 40kDa (see Figure 6). It was purified sequentially 
over a glutathione-column first and then over a Ni-TA-column. The purity of the 
recombinant protein fraction met our standards and this recombinant protein was 
used to immunize NMRI mice. 
 
 
Figure 6.  Polyacrylamide gel and Western blot of recombinant NTS. 
The recombinant protein NTS is visible at approximately 40 KDa. A. Coomassie blue 
SDS PAGE with purified recombinant NTS, an additional band is visible at 30 kDa. 
B. Western blot of recombinant NTS probed with 6xHIS antibodies. The 
recombinant protein is visible at 40 kDa.  
 
Immunization of mice and characterization of anti-NTS sera 
When immunizing mice with recombinant GST-NTS-HIS from the FCR3 S1.2, two 
slightly different immunization protocols were used in order to optimize 
immunization. Briefly, 3 mice were immunized with MPL-TDM (Sigma) adjuvant 
(MPLM1-MPLM3) and 3 mice were immunized with Immune-Easy (Qiagen) adjuvant 
250 
 150 
 100 
 75 
 
 50 
 
 37 
 
25 
 
 20 
 
 
250 
 150 
 100 
 75 
 
 
50 
 
 37 
 
25 
 
 20  
 
15 
 
 
A.         B. 
 61 
(IEM1-IEM3). The sera were tested against recombinant protein and total parasite 
protein lysates. Figure 7 shows that sera tested in Western blots recognized the 
recombinant protein GST-NTS-HIS with a band at 37 kDa. There were also multiple 
lower bands, which may represent breakdown products of the recombinant protein. 
Serum from IEM1 showed the most specific interaction, but also the weakest. In all 
other sera background bands were visible. MPLM3 showed the strongest 
interaction. 
The sera were also tested on parasite lysates to detect the full length PfEMP1 (see 
Figure 8). The pattern obtained with the sera showed two bands above 250 kDa, 
which is in the size range of endogenous PfEMP1. However, controls with pre-
immune mice sera and with other anti-PfEMP1 serum (against the ATS domain, 
kindly provided by M. Wahlgren), revealed that the recognized bands were not 
PfEMP1. As the same bands also come up in lysates of uninfected red blood cells, it 
must be cross reaction with an erythrocyte protein, most likely alpha and beta 
spectrin.  
 
 
Figure 7. Western blots for testing six mouse anti-NTS sera. 
Recombinant NTS was blotted and probed with 6 different mice sera. Lanes 1-3 
represent sera from IEM1-IEM3, and lanes 4-6 are sera from MPLM1-MPLM3. The 
apparent size of the recombinant protein is about 40kDa.  
100 
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Figure 8. Western blots of parasite lysates probed with different anti-sera. 
Lysates from parasite lines FCR3 S1.2 (lane1), 3d7 (lane 2) and red blood cells (lane 
3) were tested with pre-immune mice sera pool (A), anti-NTS mice serum pool (B) 
and rat anti-ATS (C, provided by M. Wahlgren). All sera were used 1:200. The arrow 
indicates the band expected to be PfEMP1. 
 
Sera from NTS immunized mice tested in IFA 
To rule out that epitope modification during protein electrophoresis and transfer was 
the reason for the unclear immunoblot results of total parasite protein preparations, 
all sera were additionally tested in immunofluorescence assays (IFAs). The sera were 
incubated with fixed (either acetone/methanol or glutaraldehyde/formaldehyde) 
smears on microscopic glass slides and investigated under a fluorescence 
microscope. Only 2 sera gave reasonable signals, namely IEM2 and MPLM3. All 
other sera gave no signal or showed elevated background levels, which made it 
impossible to discriminate any labeled structures. In glutaraldehyde/formaldehyde 
fixed infected red blood cells both IEM2 and MPLM3 sera showed the same 
fluorescent pattern: a sharp rim-like or tube-like structure surrounding the nucleus 
(see Figure 9) indicating localization within the endoplasmatic reticulum (ER) [86-88]. 
 63 
The dotted staining of the parasite and the red blood cell cytosol characteristic for 
PfEMP1 [43, 74] was never observed. 
Acetone/methanol fixed infected red blood cells showed a different picture and were 
only positive for mouse MPLM3 (see Figure 7B). With this fixation, the pattern was 
diffuse. A faint and fuzzy staining of the host cell cytosol was visible, but only with 
long exposure times. 
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Figure 9. IFA of infected red blood cells probed with anti-NTS mice sera using 
two different fixation methods. 
Sera MPLM3 and IEM2 were tested and the secondary antibody used was goat IgG 
anti-mouse-Cy3. 
A. Formaldehyde/glutaraldehyde fixed FCR3 S1.2 parasites. In red the rim like 
structure of the anti-NTS serum is visible. In blue is the DAPI stained genomic DNA. 
Left column: brightfield image and DAPI overlay; middle column: anti-NTS signal 
(Cy3); right column: overlay of left and middle column. I2 is IEM2; M3 is MPLM3. B. 
Acetone/methanol fixed parasites. Serum from mouse 3 MPL on FCR3 S1.2. In red 
anti-NTS (Cy3), in blue DAPI. From left to right: DAPI, Cy3, overlay, bright field. 
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A 
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5. Cloning, expression and purification of C- and N-terminal ATS fragments 
Sera raised against synthetic peptides (see section 6) can only be tested on Western 
blots with very sophisticated Western blot protocols for small peptides. 
To circumvent establishment of a peptide Western blot protocol, we generated a 
pair of recombinant proteins covering the ATS. The ATS domain was split into two 
separate domains, ATS-N and ATS-C (see schematic representation in figure 9), to 
facilitate recombinant expression. The domains were cloned into a pQE-16 vector 
expressing the cloned gene as DHFR-fusion protein. The expected size for ATS-N 
was 50 kDa and for ATS-C 59 kDa. Both domains overlapped in the middle by 6 
amino acids. Upon recombinant expression, both domains were not soluble but 
expressed in high levels and were successfully purified over Nickel column in 8 M 
urea (see Figure 10).  Protein extracts were later used as controls to assess antibody 
levels and selectivity in Western blots of sera from ATS immunized mice. 
 
 
 
Figure 10. Coomassie blue stained SDS PAGE and Western blot of recombinant 
ATS-N and ATS-C. 
Purified recombinant ATS fragments were separated by gel electrophoresis; lane 1, 
ATS-N; lane 2, ATS-C. A. Coomassie stained 12,5% Polyacrylamide gel. B. Western 
blot from 10% Polyacrylamide gel probed with anti-6xHIS antibodies. 
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6. In silico ATS analyses to select synthetic peptide candidates 
Due to a persisting lack of specific anti-PfEMP1 antibodies, we searched for new 
possible sequences to use as antigens for raising antibodies in mice. The ATS 
domain of PfEMP1 which faces the erythrocyte cytosol is not under immunological 
pressure, hence is not as variable as the extracellular portion of PfEMP1. We aligned 
all 3d7 ATS sequences to find conserved stretches (see appendix alignment 1). We 
chose three stretches (ATS1-3) within the ATS domain which have a homology 
greater than 80%. The peptide ATS1 (SDITSSESEYEELDINDIYVP) had a length of 
21 amino acids (aa), peptide ATS2 (PKYKTLIEVVLEPS) had a length of 14 aa and 
peptide ATS3 (GIDLINDTLSSGNHIDIYDEVLKRKENELFG) 31 aa. In addition we 
selected a fourth peptide (ATS4) not because of its homology but because of its 
predicted coiled-coil structure. The peptide ATS4 (LDRHRDMCEKWKNKEDILNKLK 
EEWNKENINN) was 32 aa long (see Figure 11 for details). The peptides ATS1 and 
ATS2 were modified to enhance immunogenicity as described in materials and 
methods. 
 
Figure 11. Schematic representation of the ATS domain of PfEMP1 in the FCR3 
S1.2 strain.   
Depicted in grey is the full ATS domain of PfEMP1. Blue bars represent the 
recombinantly expressed ATS-N and ATS-C domain, which overlap by the 6 amino 
acids NSMNDI. Synthetic peptides were chosen according to 3 regions with over 
80% homology shown as red boxes (ATS1-ATS3). A fourth synthetic peptide (ATS4) 
was defined according to regions of predicted coiled-coil domain. The numbers 
indicate the amino acids starting after the transmembrane domain (numbers and 
amino acids are valid for FCR3 S1.2 ATS, AF003473).    
1           64   85   88   101                              217   223       240  270             301  331                458 
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Immunization with synthetic peptides and characterization of sera 
A new adjuvant TiterMax Gold (Sigma) was used for immunization of mice with 
synthetic peptides. For every peptide, 3 mice were immunized, resulting in sera 
ATS1M1-ATS1M3, ATS2M1-ATS2M3, ATS3M1-ATS3M3, and ATS4M1-ATS4M3, 
Specificity of all sera was tested in ELISAs (see figure 10). Sera ATS1M1-3, ATS3M1 
and ATS4M2-3 showed very high titers ranging from 1:3000 to 1:10000. All ELISA-
positive sera were additionally tested in Western blots on recombinant ATS 
fragments (see Figure 13). All ATS1 immune sera recognized the recombinant N-
terminal ATS fragment but not the C-terminal fragment. Non of the ATS2 immune 
sera gave a signal in Western blots. Only sera from mouse1 from immunization with 
ATS3 recognized the recombinant C-terminal and not the N-terminal fragment. Sera 
ATS1M1-3 and ATS3M1 have high antibody titers and are specific for their antigen. 
These sera were also tested on Western blots of total parasite lysates from lab 
strains 3d7 and E8B (see Figure 14). All sera recognized two strong bands above 
250kDa. The same bands were also recognized in Western blots of uninfected red 
blood cells. As the recognized bands seem to be of erythrocytic origin, MACS 
enriched parasites were used for the preparation of protein lysates to improve the 
parasite:erythrocyte ratio. MACS is a magnetic cell sorter which can bind 
trophozoite and schizont stage iRBCs due to magnetic iron deposits in the food 
vacuole. Younger stages and RBC do not bind. The intensity of the recognized 
bands was reduced significantly in the MACS sample (Figure 14, lane 4), 
strengthening the evidence for erythrocytic origin of the recognized bands. With the 
exception of the MACS enriched sample there were no additional bands in immuno 
blots of infected red blood cells compared to blots of uninfected red blood cells. In 
the MACS purified sample there was an additional unidentified 150kDa band. Thus 
our Western blot analyses show, that none of the immune sera raised against 4 
different domains of the ATS recognized native PfEMP1 in Western blots. The 
additional band at 150 kDa in the MACS sample is not PfEMP1 as this is expected 
to be bigger than 250kDa. In Figure 12 the Western blot of ATS1 M1 is shown, 
which is representative for all ELISA positive sera. 
Furthermore, all sera were tested in IFAs on the parasite line FCR3 S1.2 to confirm 
the results from Western blots (see Figure 15). Only a very faint signal was detected 
and in accordance with Western blot results the signals was also present in 
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uninfected erythrocytes and is thus unspecific for PfEMP1. IFAs from three different 
mice immunized with ATS1 giving the strongest signals are shown in Figure 12. M3 
is shown here as an example and all other sera tested stained the RBCs as well. 
 
Figure 12. Enzyme linked immuno fluorescence assays of mice sera on 
synthetic ATS peptides. 
A.  ELISA results for ATS1 and ATS2. Mice immunized with ATS1 (ATS1M1-M3) had 
very high titers ranging between 1:5000 and 1:10000. For ATS2 only M1 and M2 
show a (weak) response. In blue: negative control on ATS1 without primary 
antibody. B. Results from ATS3 and ATS4. ATS3 M1 and ATS4 M2-3 show high 
response with titers ranging between 1:1000 and 1:10000.  
A 
B 
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Figure 13. Western blot of different mice sera on recombinant ATS N-terminal 
and C-terminal fragments. 
The C-terminal fragment (A) and the N-terminal (B) fragment of the ATS were 
blotted. The sera tested are: Lane 1,mouse 1  anti-ATS2 (ATS2M1); lane 2, ATS3M1; 
lane 3, ATS2 M2; lane 4,  ATS4 M2; lane 5, ATS1 M1; lane 6, ATS1 M2; lane 7, ATS1 
M3; lane 8, anti-6xHIS antibody.  
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Figure 14. Western blot of parasite lysate probed with ATS1 M1 serum. 
Serum (1:200) from mouse1 immunized with ATS1 was tested against different 
lysates. Strong recognition of a protein from the erythrocyte is visible around 250 
kDa. Lane 1, erythrocyte lysate; lane 2, Pf3d7 lysate; lane 3, E8B lysate; lane 4, 
MACS purified Pf3d7 lysate. As positive control recombinant ATS-N was included 
(+). 
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Figure 15. IFA of Plasmodium falciparum 3d7 infected red blood cells probed 
with sera from ATS1-immunized mice. 
Formaldehyde fixed 3d7 cultures were stained with DAPI and probed with 3 different 
mouse sera ATS1 M1-M3. For M1 and M2 structures in the infected red blood cell 
were labelled. For serum from M3 an uninfected red cell was stained. Columns from 
left to right: DIC image, anti-ATS sera Cy3, DNA DAPI stain, overlay. 
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Chapter 3 
 
Dicussion 
 
Expression of large recombinant proteins 
Investigations on recognition frequencies of PfEMP1 are mainly based on the DBL 
domain. To obtain a broader picture of the differential recognition of PfEMP1 
variants, we tried to express large fragments of this protein from the sequenced 
strain Plasmodium falciparum 3d7. We established long range PCR and were able to 
amplify DNA up to 8kb long. The difficulties arose with cloning of the amplified 
fragments. The E.coli expression vector chosen for this experiment had a size of 
about 5 kDa. Despite the numerous long range PCR fragments we obtained, cloning 
efficiency was poor. This ineffective cloning strategy is most probably due to the 
size of the inserts, as the probability for re-ligation drops with increasing insert size. 
Nevertheless, we generated one construct with a 4 kb insert. However, the 
expression of this fragment was impossible although sequencing revealed that the 
insert was in the expected frame. Retransfection of the plasmid into a bacterial 
strain coding for rare tRNAs did not improve expression at all. The protein encoded 
on the plasmid had an expected size of almost 140kDa and we concluded that this 
size overstressed the translation machinery of E.coli [83]. This is supported by the 
fact that almost no E.coli protein visible on a SDS gel exceeds 100kDa (see Figure 3, 
Results).  
 
 
Random cloning of cDNA 
Because we could not solve the cloning and expression problems with large 
PfEMP1 fragments we decided to move to a more random approach. Bull et al. 
showed by agglutination assays that parasite isolates, which cause severe disease, 
are frequently recognized by heterologous sera whereas parasites causing mild 
symptoms present uncommon antigens and are thus less frequently recognized [89]. 
Based on these findings we wanted to narrow down the differential recognition to 
certain domains of PfEMP1. We decided to generate an E.coli expression library that 
expresses random peptides of plasmodial proteins. Two identical copies of the 
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library should be probed with either non-immune or immune sera. Differentially 
recognized clones would be analyzed subsequently. 
We isolated RNA from cultured parasites and reverse transcribed it into cDNA. The 
library constructed from this cDNA was heavily contaminated with ribosomal rRNA, 
which made it impossible to go on with the serology. We tried to improve our library 
and reduce the complexity of the sample by isolating full length varmRNA from 
crude RNA samples [55]. For this the mRNA is hybridized to an immobilized probe  
specific for the ATS domain and subsequently transcribed. But the introduction of 
this step dramatically reduced the amount of cDNA obtained. Irrespective of the 
detection of var cDNA by PCR it was not possible to clone it. It was concluded that 
the low amount was the reason for negative cloning result. The amplification of the 
mRNA prior to cDNA transcription should overcome this problem. A method 
exploiting the template switching effect of reverse transcriptase was used to 
introduce linkers to the cDNA. With the known linker sequence the cDNA could be 
PCR amplified afterwards. Amplification and cloning of the modified cDNA worked, 
however the resulting library contained again only ribosomal and transfer RNA. 
Despite the enrichment of var mRNA, the contamination of other RNAs was so 
intense that the library could not be used. A more stringent washing step introduced 
after hybridization of the var mRNA resulted in total sample loss.  
Too many drawbacks and snags let us terminate these approaches to identify new 
domains which are differentially recognized by adult and children sera. From there 
on we focused on DBL domains only and performed serological studies (see also 
Chapter 4). 
 
Expression of short fragments from different domains of PfEMP1 as antigens 
Rosetting is a major virulence factor of a malaria infection. The dissection of the 
molecular basis of rosetting is still ongoing and not yet completely understood. 
Serum factors and host proteins play an important role in rosetting as they act as 
bridging molecules [30]. Luginbühl et al. found that only three proteins can restore a 
rosetting phenotype in an otherwise protein free medium. The host proteins 
implicated in rosette formation are albumin, factor D, and anti-Band3 antibodies. It is 
further known that CR1 on the erythrocytes surface is involved in rosette formation 
[78]. The parasite proteins conferring the rosetting phenotype, however, are not yet 
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clear. The only evidence, so far, is that DBLα domains bind to CR1 and antibodies 
directed against DBLα block rosetting [90]. In in vitro rosette re-formation a 65kDa 
fragment has been shown to be cleaved off the iRBC with factor D. This was not 
observed with RBCs only or without factor D [31]. Being a protease, factor D is 
suspect of modifying the iRBC surface inducing rosette formation. However, factor 
D is a highly specific protease with the only known substrate factor B. To clarify the 
origin of the cleaved fragment and because there is a possibility that PfEMP1 is 
involved in rosetting, we planned to generate PfEMP1 antibodies. First we focused 
on the N-terminal and the C-terminal domains of PfEMP1. Therefore we 
recombinantly expressed the NTS and the ATS domain. The use of recombinant 
ATS was discontinued, as it was not possible to purify the insoluble protein 
satisfying purity. We could not identify expression conditions which led to soluble 
ATS or prevented the breakdown of the protein as visible on Western blot (see 
Figure 5B and C). Late induction times, reported to improve such problems [79], did 
not increase the yield.  
The NTS domain, in contrast, was expressed as soluble protein and purified 
subsequently via the 6xHIS- and the GST-tag. This co-purification gave pure protein 
acceptable for mice immunization. Two different adjuvants were used to increase 
the probability of a good response the antigen. On Western blots all sera were 
positive on the recombinant protein (see Figure 7). However on blots of parasite 
lysate the anti-sera did not recognize PfEMP1. The immunogenicity of the 
recombinant proteins may result from the recognition of GST, as GST was also 
present in the immunized antigen. When using the mouse sera in IFA, rim-like 
structures stained which seems to be the ER [86-88]. Most proteins destined for 
export are co-translated into the ER [91]. Even though PfEMP1 contains no classical 
PEXEL motif, it contains a modified variant within the first DBL domain [69]. In some 
organisms signal sequences are cleaved off during the translocation in the ER an it 
is possible that the NTS is cleaved off together with the signal sequence in the ER. 
Although it is unknown whether signal sequences are cleaved off in Plasmodium, 
recently it was reported that the PEXEL motif is cleaved in the ER (HH. Chang, 
Woods Hole, unpublished). Such N-terminal processing of PfEMP1 would explain 
the results obtained in IFA and Western blots. Therefore it cloud be possible that 
PfEMP1 was present in the protein lysates used for Western blots but was already 
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trafficked through the ER and did not contain the NTS domain anymore. This would 
explain why Western blots with these sera on whole protein lysates were negative. 
In IFA, the signal obtained could represent signal sequence which has already been 
cleaved off and is in the ER or the complete protein on its way to the PVM. Further 
investigation is required to clarify if the mice anti-NTS sera generated really bind to 
the endogenous NTS domain or if the IFA results are an artifact. The plan of using 
this antibody to detect the processed fragment after rosette formation was 
abandoned, as sera characterized were not completely satisfying.  
 
Protein expression in general – size matters 
Recombinant protein expression of plasmodial proteins seems to be difficult in 
general. In a large experiment where 1000 ORFs were cloned for expression, only 
337 expressed a protein at all; from those only 63 where soluble [83]. These 
numbers indicate that soluble expression of malarial proteins is a challenging task. 
In the same publication the expressability and the solubility were correlated with the 
isoelctric point, the size of the protein and the homology to E.coli. Authors 
concluded, that the smaller the protein, the more acetic the pI and the closer the 
homology to E.coli, the greater is the chance of soluble recombinant expression. 
The predicted expressability of proteins was not the criteria for the choice of the 
proteins expressed in our work. But in a retrospective analysis of all proteins 
expressed we can conclude the following: In our case the homology to E.coli could 
not be taken into account, as there is no homology of PfEMP1 to the bacterial 
proteome. The acidic pI e.g. for the ATS did not enhance solubility in our work. The 
only factor that influenced the expressebilitiy (but not the solubility) was the size. 
The large PfEMP1 fragments did not express at all and the ATS domain was better 
expressable when it was split into two smaller fragments.  
The proteins expressed in this thesis were all but one insoluble. However, the 
expression of soluble fragments is generally possible, as it has been demonstarted 
for MAHRPs and ETRAMPS in our lab [72, 92]. A real determinant for the solubility of 
plasmodial proteins expressed in E.coli remains to be elucidated. Alternatively, more 
efforts on dialysis and refolding of expressed proteins could help to increase the 
solubility.  
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Synthetic peptides as antigens in mice 
Since we were unable to generate antibodies against the NTS domain, we focused 
again on the ATS domain. The C-terminal domain of PfEMP1 qualifies for the 
generation of pan-specific antibodies, as this part is intraerythrocytic and not 
subject to antigenic variation. The recombinantly expressed ATS was impossible to 
purify and was prone to degradation. The ATS was insoluble and the GST tag 
implicated for a second purification step was thus useless. We had expected the 
ATS to be in the soluble form as it is the domain with the highest prediction of 
solubility of all PfEMP1 domains [93]. We changed our approach from recombinant 
protein expression to synthetic peptides. Synthetic peptides harbor a lot of 
advantages compared to recombinant proteins. They are pure, soluble and contain 
only the desired sequence against which antibodies should be raised, i.e. no tags 
and no multiple cloning sites. The poor antigenicity of synthetic peptides can be 
overcome by antigenicity increasing modifications such as  conjugation to large 
antigenic proteins like the Keyhole Limpet Hemocyanin (KLH) or by connecting 
several peptides to a star-like structure. We chose 3 peptides based on a 3d7 
sequence alignment of all ATS domains. In the conserved regions the consensus 
sequences reached similarities of over 90% and we selected 3 peptides from these 
areas. An additional fourth peptide was chosen from the FCR3 S1.2 ATS domain 
due to its predicted coiled-coil structure. The self-assembly of these structures is 
used to mimic a natural conformation of the otherwise linear peptide. Using Titer-
Max-Gold which is an oil-in-water emulsion, a single dose of antigen is enough to 
elicit a boosted antibody response. Subsequent boosting is therefore not necessary 
and consequently requires less antigen. 
To perform Western blots with peptides is a rather complicated procedure for 
several reasons as listed in the following. Firstly, as peptides are very small they 
often travel thru the nitrocellulose membrane. Furthermore, hydrophobic interactions 
with the membrane are weak also according to their size. This often leads to the loss 
of the antigen during washing steps. To overcome the problem of performing 
Western blots with the synthetic peptides to test the sera, we chose a different 
approach. In order to test whether the peptides would elicit antibodies that 
recognize the ATS domain we split the ATS domain into two and expressed each 
fragment  in E.coli. Both parts were insoluble and expressed in high levels. We used 
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these proteins as antigens to test the mouse sera in Western blots. The 
immunization yielded 4 different sera, which were positive in Western blots and 6 
sera that were positive in ELISA. The ELISA plates were coated with the peptide but 
not with recombinant protein. The sera which were positive in ELISA but not in 
Western blots therefore probably recognized specific conformations of the peptides 
or the ends of the peptides which are not present in recombinant proteins in 
Western blot. These sera were excluded from further analysis. The other 4 sera were 
tested on different parasite lysates. Unfortunately, all sera recognized a host protein 
also present in uninfected red blood cells, most probably it is human spectrin. This 
crossreactivity has been reported by other groups too [43]. Consequently, lysate 
conditions were modified to obtain protein fractions that are enriched for parasite 
proteins.  The best possibility to achieve this was to purify iRBC over a magnetic cell 
sorter. The elution contained almost 100% parasitized cells. This cells were Triton-
X-100 lysed, which enriches for integral membrane proteins. This reduced the 
complexity of the sample as was seen because the background recognition of 
spectrin was reduced compared to other methods (see Figure 14). Nevertheless, no 
endogenous PfEMP1 was detected. It is not clear whether the epitope on the 
endogenous protein is somehow altered by the blotting procedure or whether the 
expression level of PfEMP1 in cultured parasites is below the detection limit. 
However, others have shown perfectly stained PfEMP1 with antiserum [76, 94]. But 
these antisera were either affinity purified or preadsorbed on ghosts. Our initial 
efforts on such purification steps ended with complete loss of reactivity of our sera 
(data not shown).  
Also, none of the sera labeled PfEMP1 in IFAs in a way previously shown [43, 74]. 
We observed occasional staining of uninfected RBCs, which is consistent with the 
results from our Western blots in which uninfected RBC also gave a signal. 
 
For future work, further efforts in the development of pan-specific antiserum should 
include the generation of monoclonal antibodies to reduce cross-reactivity and the 
selection for a high affinity isotype. Additionally more efforts can be done on the 
affinity purification of the polyclonal sera. 
 78 
 79 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: 
 
Recombinant expression and serology of DBL domains 
isolated from patients with severe or asymptomatic malaria 
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Introduction 
 
Switching of var genes 
One way how Plasmodium falciparum escapes the immune system is by antigenic 
variation. PfEMP1 is expressed on the surface of erythrocytes and mediates 
cytoadherence. It is encoded by the var multigene family. There are about 60 
different var genes encoded in the parasites genome, however, only one is 
expressed at a time [56, 95, see also Chater1; Introduction]. From the parasite’s 
perspective, this mutually exclusive expression is a “two edged” situation: On the 
one hand, the parasite has to maintain the expression of the same var gene through 
several cycles to not exhaust the repertoire to early. On the other hand however, it 
has to switch to a new variant as soon as the immune system starts to defend the 
currently expressed PfEMP1 [96]. A switching rate of 2,4% per generation was 
calculated for in vitro cultures [97], but rates for in vivo infections seem to differ 
substantially. Artificial infection of non-immune adults resulted in a switching rate of 
16% for the initial switching event, though switching rates of later events decreased 
and seemed to be dependent on various factors such as the var gene itself and host 
conditions [98]. It was also shown that the expression pattern of central var genes 
was more stable than the expression of subtelomerically located var genes, which 
switch faster to alternative loci [99]. But switching rates are not correlated with the 5` 
promoter group (ups) [96]. The regulation of this mutually exclusive transcription is 
not yet completely understood but involves histone modifications [100] and the 
location within the nucleus [101]. var gene regulation will however not be discussed 
in this chapter. 
 
 
Correlation of var variant and disease outcome 
var gene sequences are grouped in four different groups (A, B, C, E) based on their 
upstream sequences (ups). The regulatory differences between these groups remain 
to be elucidated. Different promoter elements have been found in upsB and upsC 
var genes. A subtelomeric var promoter element 1 (SPE 1) was locted in upsB var 
genes and the chromosome-central var gene promoter element (CPE) was only 
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found in ups C var genes [53]. This implies a differential regulation of these two 
types of var genes. What role they play in regulation and silencing is currently under 
investigation.  
Malaria pathology however, has be associated with group specific expression. An 
upregulation of upsB var genes was found in severe and mild malaria cases in Africa 
and PNG, whereas upsC was correlated with asymptomatic cases [54, 102]. Bull et 
al. [103] used the DBL domain to classify different groups of PfEMP1 variants. The 
basis of these classifications is the number of cysteine (cys) residues as well as 
positions of limited variability (PolV). The “Bull-groups” 1-3 represent the 2cysDBL 
group, which represents the upsA and small subgroup of upsB var genes, whereas 
the groups 4-6 with 4 cysteine residues cover upsB and upsC var genes [104]. 
2cysDBL/upsA was associated with the rosetting phenotype [104, 105], cerebral 
malaria in children [104] and non-cerebral severe malaria in adults [62]. It was also 
shown that it is possible to select the laboratory strain 3d7 for PfEMP1 variants 
normally expressed in severe cases [106]. 
The best understood correlation of disease and expressed var gene is that of 
var2CSA (reviewed in [22, 107]). Women who have previously acquired immunity 
against malaria can develop an episode upon pregnancy or have pregnancy 
complications as preterm delivery or stillbirth. The reason is that chondroitin sulfate 
A (CSA) is expressed in the placenta [108]. This low sulfated glucosaminocglycan 
(GAG) represents a new interaction possibility for surface molecules of the iRBC. 
After the first or second pregnancy women are protected from PAM (pregnancy 
associated malaria). The development of antibodies against special domains from 
that var gene seems to prevent binding of iRBCs to the placenta. Additionally, these 
domains seem to be not as divers as expected because sera from protected women 
bind to placental parasites from geographically distinct regions [24]. The 
phenomenon that antibody mediated protection against a very special PfEMP1 
variant is possible and even relatively long lasting, generates hope for the 
development of a vaccine. Even though it would not confer sterile immunity, it could 
prevent severe disease and pathology. 
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Rare and prevalent variants of PfEMP1  
The repertoire of var genes in one parasite is about 60, but the worldwide repertoire 
of all wild type PfEMP1 is probably endless. It is known that the antibody pool in a 
semi-immune individual is sufficient to protect from a malaria episode, as is the case 
for semi-immune adults living in endemic areas in Africa. However, such individuals 
have never seen all PfEMP1 variants because the worldwide PfEMP1 repertoir is 
endless. Nevertheless, semi immune individuals are protected from malaria. 
Obviously, there seem to be antibodies against specific PfEMP1, which contribute 
more to protection from severe disease than other anti-PfEMP1 antibodies. 
 
PfEMP1 is considered to be the main interaction partner to host cell surface 
receptors, and antibodies against PfEMP1 prevent cytoadherence and therefore 
severe malaria. Although PfEMP1 must be very diverse to trick the immune system, 
it must also contain conserved domains which confer binding to the receptors. 
Modifications in binding domains will indeed account for antigenic variation but will 
reduce the binding efficiency to their receptor. Not all variants of PfEMP1 will have 
the same binding affinity to the host endothelium, thus making some variants more 
virulent than others. 
Bull et al. [89] used agglutination assays to show that host immunity develops 
against PfEMP1. In their experiments they took serum samples from children during 
a severe malaria episode and after convalescence. They also cultivated the 
parasites causing this malaria episode. They found that patient’s convalescence 
sera agglutinated the cultured parasites whereas the acute sera did not. This 
showed that the diversity of PfEMP1 is reflected in the fact that normally only 
parasite isolates matching the sera will agglutinate, but this sera will not bind to 
parasite isolates from other patients [89]. Immunity against malaria is variant 
specific. The same authors found that parasite isolates from patients with severe 
disease are recognized frequently by different serum samples thus representing 
common antigen variants. Parasite isolates that are not widely recognized 
(expressing a rare type of PfEMP1) are generally not obtained from severe case 
patients. This supports the hypothesis of a trade-off between variability vs binding 
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efficiency. An immune adult that exhibitis a patchwork antibody repertoire against 
the common isolates (good cytoadherence= severe disease) will not develop a 
severe episode since the rare isolates (bad cytoadherence = mild/no disease) can 
proliferate.  
 
Organ specific expression of PfEMP1 
The capacity of P.falciparum to cause severe malaria is at least in part due to the 
ability to cytoadhere. As the host cell receptors are numerous and PfEMP1 is 
diverse, the site of adherence can be distributed in different tissues. Montgomery et 
al. [109], investigated the genotypes (based on the msp2 locus) sequestered in 
different organs as well as the var types expressed. They found that over 100 
different var types were expressed in a single patient and up to 10 different per 
genotype and per organ. This is conflicting with other studies where less than 2 
different var types were found per genotype [55]. They also investigated the 
correlation of genotype or var expression with specific tissues. Despite the random 
distribution of different genotypes in the body without genotypic preference in 
special organs [110], there was tissue specific expression of var types. The organ 
dependent var expression was obvious for brain and heart mirovasculatur [109]. Not 
only that the same var types were found in one organ in one patient but the same 
types were also found in the same organ in other patients from a geographically 
distinct location. These patients with fatal severe malaria, which shared some var 
types of parasites sequestered in the brain, were from different villages in Malawi. 
In the same study they found that asymptomatic children who died of other causes 
than malaria had almost no sequestered parasites in the brain, regardless of 
extremely high peripheral parasitaemias with more than 300000 parasites per micro 
liter blood. 
 
 
These findings support the feasibility of a vaccine containing PfEMP1 domains, 
because within the endlessly large repertoire of worldwide PfEMP1 variants, 
apparently not all PfEMP1 variants are equally pathogenic. By tackling the disease-
causing variants, the repertoire of PfEMP1 candidates could be narrowed down to 
key candidates of high pathogenicity. 
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In conclusion, even though PfEMP1 is very diverse it appears that only a relatively 
small subset of var types is responsible for severe disease. This has already been 
shown for PAM where also the same var type is dominant in different patients as 
described above. 
 
In this work we have further investigated in the role of certain PfEMP1 variants in 
severe and asymptomatic cases. We selected DBL domains from var genes 
expressed in severe episodes and asymptomatic infections. We recombinantely 
expressed them in E.coli and measured antibody levels against these DBL 1α 
domains in sera from semi-immune adults. We found that DBL domains from 
patients with severe malaria are more frequently recognized than DBL domains from 
patients with asymptomatic malaria. We used the same recombinant DBL domains 
and tested sera from children which were collected at two different timepoints within 
a longitudinal study in Tanzania. The children had no acute malaria episode in 
between the two timepoints.  
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Chapter 4 
Materials and methods 
 
Isolation of DBL domains from patients with severe and asymptomatic malaria 
Blood samples were collected in Tanzania from children with severe malaria (8) and 
from asymptomatic children (7). Total RNA was extracted, full-length var mRNA 
isolated and reverse transcribed from each sample as described below. 
Subsequently the DBL domain was PCR amplified from the cDNA using primers 
dbl_fwd and dbl_reverse (see appendix for sequence information) and cloned into 
pGEM-T (Promega) vector for sequencing (performed by Paschal Mugasa). For each 
patient, plasmids were isolated from 50 clones and subsequently sequenced. 
 
Plasmodial RNA extraction and complete cDNA synthesis 
Blood samples from Plasmodium falciparum infected patients were resuspended in 
5 volumes Trizol® (Invitrogen). RNA was extracted from the lysate with 0.2 ml 
chloroform per ml Trizol® and precipitated with 3 volumes of isopropanol. To 
improve purity the pellet was again resuspended in Trizol® (0.5 volumes, compared 
to the first extraction step), extracted with chloroform and then precipitated. The 
precipitated DNA was digested by two subsequent incubations with RQ1 RNAse 
free DNAse (Promega) according to the manufacturer’s protocol, in the presence of 
RNAse inhibitors. After each DNAse digest, the RNA was extracted and precipitated 
as described above. cDNA synthesis was performed using sensiscript® reverse 
transcriptase with random hexamer primers, in accordance with the respective 
manufacturer’s protocol. RNA amounts used in a cDNA synthesis reaction varied 
according to the parasitaemia of the blood sample. A control reaction without 
reverse transcriptase was always included. 
 
Reverse transcription of RNA 
RNA samples either from bead hybridisation (full length var mRNA) or crude were 
mixed with 3.5µl 0.1M DTT, 2µl RNAse inhibitor, 7µl 10x RT-Buffer (sensiscript/M-
MuLV), 7µl 5mM dNTPs and RNAse free dH2O to 70µl. The reaction mix was split 
into a 50µl and a 20µl aliquot. To the 50µl aliquot 2µl of reverse transcriptase was 
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added, the other was left as negative control without enzyme. Both tubes were 
incubated at 37°C for 90 min. After the reaction the RNA:DNA duplex was melted at 
93°C for 3 min and the RNA was digested with 1µl of RNAse A (1mg/ml) at 37°C for 
20 min. The single strand cDNA was stored at -20°C. 
 
Full length var mRNA extraction 
To extract only the full-length var mRNA transcripts from a total RNA preparation, a 
hybridization technique was used as described in the following: 1 pmol of a 
biotinylated oligonucleotide complementary to the ATS domain was incubated 
together with the total RNA in hot binding buffer (0.5M LiCl, 1mM EDTA, 10mM Tris, 
pH7.5). After slow cooling from 65°C to 4°C over 30 minutes, 200 µg of streptavidine 
coated magnetic beads (dynal) were washed, dissolved in 5.5 M LiCl and added to 
the RNA:DNA hybrid and incubated for 30 minutes at 37°C on an over-head shaker. 
Beads were collected on the wall of the reaction tube by a surrounding magnet and 
washed 3 times with wash buffer (10mM Tris, 1mM EDTA, 0.15M NaCl, pH 7.5)[55]. 
Reverse transcription was performed directly on the RNA hybridized to the beads as 
described previously.  
 
Cloning of DBL domains 
The DBL domains had to be amplified from the plasmid preparations for re-cloning 
in expression vector pQE-16 (Qiagen). The primer pair dbl1_fwd and dbl1_reverse ( 
see appendix for sequence information) containing the restriction sites EcoNI and 
BglII were used. The PCR product was purified (PCR clean-up, ROCHE) and 
digested with EcoNI and BglII. The vector was digested with the same enzymes, 
purified and ligated with T4 ligase (NEB) according to the manufacturer’s protocol. 
The ligation was phenol:chlorophorm extracted, precipitated and resuspended in 
10µl dH2O. Ice cold electrocompetent M15 E. coli (Qiagen) were mixed with the 
resolved ligation and electroporated (single pulse, 2500V, 0.2cm gap, 5ms). Bacteria 
were spread on agar plates and screened for correct inserts by PCR with primer pair 
pQE_fwd and pQE_reverse (see appendix for sequence information).  
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Recombinant expression of DBL domains 
50ml bacterial culture medium terrific broth containing the antibiotics ampicilin 
(100µg/ml) and kanamycin (25µg/ml) were inoculated with 1ml over night culture of 
M15 E. coli harboring the pQE plasmid with the DBL domain. The culture was 
incubated at 37°C and induced with a final concentration of 1mM IPTG when OD600 
was 0.8. Four hours later bacteria were harvested by centrifugation at 8000g for 15 
minutes and stored at -20°C until further use. 
 
Purification of recombinant DBL domains 
The bacterial pellet was lysed in inclusion body lysis buffer (50mM Tris pH 8, 100mM 
NaCl, 5mM EDTA, 0,5% Triton-X-100, 0.1mM PMSF and 1mM DTT) supplemented 
with 100µg/ml lysozyme and 10µg/ml DNAse (adapted from [111]). The slurry was 
sonicated 5 times 10 seconds in 10 second intervals with a microtip sonicator (50% 
duty cycle, output control 5).  The insoluble proteins were separated by 
centrifugation at 10000g for 30 minutes. The supernatant was discarded and the 
pellet resuspended in inclusion body lysis buffer again. This step was repeated 3 
times. In the last resuspension step of the insoluble pellet, PBS was used instead to 
avoid Triton-X-100 in the further purification steps. The washed pellet was 
resuspended in Urea buffer (8M Urea, 300mM NaCl, 10mM Tris pH 8) and mixed 
with 0.5ml Ni-TA-Agarose beads (Qiagen). The protein was further purified 
according to the manufactures protocol (Qiagen, the expressionist). Proteins were 
eluted from the beads with low pH elution buffer (8M Urea, 300mM NaCl, 10mM 
Tris, pH 4,5). Eluted proteins were stored at 4°C. 
 
Purity and quantity assessment 
Purity and quantity of eluted proteins was checked on SDS PAGE and stained with 
Coomassie blue. Quantity was estimated from marker bands with known protein 
concentration. Fractions containing the pure protein were pooled and again 
measured in a spectrophotometer at 280nm (NanoDrop), and then stored until use 
at 4°C. 
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ELISA of DBL domains with human sera 
Maxisorb 96 well ELISA plates (Nunc) were coated over night at 4°C with 10µg/ml 
recombinant protein in PBS. Plates were washed once in an ELISA washer and 
blocked for 1 hour at room temperature with 75µl 5% non-fat milk powder in PBS 
0.01% tween 20 (PBS-T). Then, plates were washed again and incubated with serial 
dilutions of human sera starting from 1:200 in 1% non-fat milk powder in PBS-T (see 
table 2). After incubation for 2 hours at room temperature, the plates were washed 
twice in the ELISA washer and then incubated with the secondary antibody (goat 
anti-human IgG alkaline phosphatase labeled (1:5000)) in 1% non-fat milk powder in 
PBS-T for one hour at room temperature. After washing, the plate was developed 
with PNP (p-Nitrophenyl-Phophate 1mg/ml) in alkaline substrate buffer (160mM 
NaHCO3,130mM Na2CO3, 1mM MgCl2, pH 8,6) and measured in an ELISA reader at 
405nm.  
 
Table 1. ELISA plate layout. 
In the column in yellow serum dilutions are indicated. In blue the different serum 
samples 1-10 tested in the experiment are shown. Positive and negative controls 
remain the same for all experiments. As positive control goat anti-6xHIS antibodies 
were used, and the negative control was a serum pool from European adult blood 
donors with no history of traveling in malaria endemic areas. 
 
ELISA calculations 
100 sera were tested on all different DBL domains (15 in total). As all recombinant 
proteins contain the DHFR tag, all sera were additionally tested on DHFR to assess 
the background.  All OD405 values were recorded and were corrected for the DHFR 
recognition by subtraction: OD405Sera1 – OD405DHFR. The corrected values were 
plotted against the logarithmic dilution. The mean of the negative values plus 2 
Dilution Sera 
 positive 
control 
negative 
control serum1 serum2 serum3 serum4 serum5 serum6 serum7 serum8 serum9 serum10 
1:200             
1:600             
1:1800             
1:5400             
1:16200             
1:48600             
1:145800             
1:1312200             
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standard deviations gave the threshold. The endpoint titer corresponded to the 
dilution were the curve of the plotted sera meets the threshold line.  The threshold 
was calculated for each plate individually.  
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Chapter4 
 
Results 
There are approximately 60 plasmodial var genes coding for variants of PfEMP1. 
There is several evidence indicating that PfEMP1 plays a crucial role in host immune 
evasion and thus represents a key virulence factor (as reviewed in [25, 112]). 
However, it is to date unclear why this PfEMP1 repertoire is so big and what 
differences might exist in terms of virulence/pathogenicity between the different 
PfEMP1 proteins. In this work we wanted to test how recombinantly expressed DBL 
domains of PfEMP1 from parasites of severely ill patients versus DBL domains from 
parasites in asymptomatic cases are recognized by sera of semi immune adults. We 
hypothesize that semi immune adults have higher titers against DBL domains 
deriving from severe cases than against asymptomatic cases. The rationale behind it 
is that adults who are semi-immune (thus not sick) are better protected because 
they recognize the repertoire of PfEMP1-DBL domains causing severe pathology 
better than those causing asymptomatic malaria. 
 
To test our hypothesis we have chosen a sero-epidemiological approach and 
assessed antibody titers of 100 semi immune adults from asymptomatic malaria 
cases of a cross-sectional study in Papua New Guinea. Sera titers were assessed 
against 15 different recombinantly expressed DBL sequences from PfEMP1. Seven 
of those DBL domains were isolated from severe malaria patients and seven were 
from asymptomatic cases. One additional DBL domain was also expressed, but 
later excluded from analysis because it did not represent the dominant infection. 
These DBL domains were termed either “severe DBL domains” when derived from 
sequences of severely ill patients, or “asymptomatic DBL domains” when derived 
from patients with asymptomatic malaria.  
We also tested sera from 34 children deriving from a longitudinal study for their DBL 
recognition at baseline and six month later. Importantly, these children did not suffer 
from a clinical episode between the two time points. By testing which DBL domains 
were recognized by these children at two different time points, we were able to 
study the dynamics of the antibody repertoire. 
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Eight recombinant DBL domains sequences were from severe case (ISM) patients 
and 7 from age matched asymptomatic children (IAM).  We did a ClustalW alignment 
to test if clusters were identifiable. As shown in Alignment 1, there was no clustering 
of severe and asymptomatic DBLs in an amino acid sequence alignment  
 
 
Alignment 1. Alignment of 15 DBL protein sequences of Plasmodium 
falciparum erythrocyte membrane protein 1. 
Amino acid sequences from DBL sequences derived from parasites infecting severe 
ill malaria patients (ISM) and asymptomatic samples (IAM) were aligned. Numbers 
correspond to the different isolate IDs (clustalW, default settings). 
 
Expression of DBL domains 
15 DBL domains were successfully expressed as DHFR fusion proteins with a 6xHIS 
tag (Figure 1). Additionally, recombinant DHFR-6xHIS was expressed as control. All 
proteins were expressed in E. coli in high levels but were insoluble. Purification of 
recombinant proteins resulted in very pure highly concentrated recombinant 
proteins. Concentration was at best 3mg/ml in a volume of 2.5 ml from a 50ml E. 
coli culture.  
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Figure 1. Coomassie stained polyacrylamide gel of recombinant expressed 
DBL domains. 
Nine different DBL domains purified over a Nickel column were size-separated on a 
12% SDS PAGE and stained with Coomassie blue. Samples were diluted 1:100 from 
original elution. M, marker in kDa; lanes 1-9 show the first 9 expressed DBL 
domains, in detail: ISM51, ISM16, ISM3, ISM33, IAM10, IAM11, IAM17, IAM12, 
IAM18. 
 
 
Western Blot of DBL domains with a positive serum pool 
To test for contaminations not visible in Coomassie stained gels, all purified proteins 
were blotted and probed with a positive serum pool from semi immune adults from 
Papua New Guinea as shown in Figure 2. All DBL domains were recognized at least 
by one serum, thus were immunogenic. The DHFR recombinant protein was also 
weakly positive. The blot was over exposed to amplify even weak signals. 
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Figure 2. Immunoblot analysis of recombinantly expressed DBL domains. 
20 ng of 15 different recombinantly expressed DBL domains were probed in 
Western blot with serum from Papua New Guinea.  DBL domains are visible as clear 
bands at expected sizes between 35 and 40 kDa. DHFR (D) runs at an expected size 
of 25 kDa. Lane 1-15: DBL domains 1-15; D, DHFR; M marker in kDa. DBL domains 
in detail: ISM51, ISM16, ISM3, ISM33, IAM10, IAM11, IAM17, IAM12, IAM18, IAM7, 
ISM48_1 (minor), ISM48_2, ISM49, ISM51. The DBL ISM48_1 was the minor clone 
and was excluded from analysis. 
 
ELISA with adult sera show that severe DBLs are more often recognized 
To investigate frequencies of recognition of the different sera, we performed 
enzyme-linked-immunosorbent-assays (ELISAs). Briefly, recombinantly expressed 
antigens were immobilized in 96 well plates and sera binding was tested. Endpoint 
titers were measured from 100 adult sera from asymptomatic malaria cases of a 
cross-sectional study in Papua New Guinea. Data sets were assessed as shown in 
Table 3. All 100 sera recognized at least one recombinant DBL domain. There were 
two sera samples that recognized all 15 domains tested (see Table 1, SUK52, 
SUK93). There were striking differences in the recognition of different DBL domains. 
The three most frequently recognized domains were IAM11 with 72%, ISM3 with 
73% and ISM51 79%. Two of those derived from the severe DBL group and one 
from the asymptomatic group. The three least frequently recognized antigens were 
IAM12 in 15%, IAM10 in 16% and ISM 48 in 16% of all sera tested. Two of these 
DBL sequences were from the asymptomatic group and one was a severe case.  
 
 95 
To obtain a cleverer picture of the recognition of different frequencies for severe and 
non-severe DBL domains, the endpoint titer table was condensed to show only 
“recognition” or “no recognition”. For each of the 100 sera from semi immune 
adults, the number of recognized antigens (severe DBL vs asymptomatic DBL 
domains) was counted. The 7 severe DBL domains were recognized 295 times by 
100 sera and the 7 asymptomatic DBL domains were recognized 213 times (see 
Graph 1A). Thus, severe DBL domains were recognized 1,4 times more often than 
asymptomatic DBL domains. Furthermore, all sera were grouped depending on their 
frequency of recognition. Groups from 0 (no DBL domain recognized) to 7 (all DBL 
domains tested recognized) were plotted in a histogram (Graph 1B). The number of 
sera recognizing asymptomatic DBL domains is high only for the “0 and 1 DBL 
recognized group”. In the case of severe DBL domains the recognition frequency 
peak is shifted towards higher numbers and peaks at 2 DBL domains recognized. 
Two or more DBL domains were recognized more often from the same sera when 
they were severe DBL domains. The results of all ELISA experiments are shown in 
the following Tables 1 and 2. 
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Table 1. ELISA endpoint titers of semi immune adult sera tested on different DBL domains 
  IAM 11 IAM 5 IAM 7 IAM 12 IAM 17 IAM 18 IAM 10   ISM 3 ISM 51 ISM 16 ISM 48 2 ISM 33 ISM 48 ISM 11 ISM 49 
SUK 4 200 600 200        400 1000      
SUK 8 1000 500        2000 2000  800  300   
SUK 11 500         300 400       
SUK 12 1000 500 500       800 2000  400   300 600 
SUK 13 200                 
SUK 14 3000                 
SUK 16 500  2000       400 600  200     
SUK 21           300       
SUK 22          200 2000       
SUK 24          2000 10000       
SUK 25                  
SUK 26            1000      
SUK 27 4000         2000 1000 500      
SUK 28 300         200 400 1000     300 
SUK 29 500 400    200    400 4000 600 300   200  
SUK 30 900 400        1000 3000  1000  800   
SUK 31 300 300        5000   700     
SUK 32          2000        
SUK 35 500         900 2000 700 500  400   
SUK 38 10000         900 1000 700 1000     
SUK 39 200         800  800 400  200   
SUK 40 500 200        400 4000  300     
SUK 41    1000 1000 1000 1000   2000  800  1000   1000 
SUK 43 1000          1000       
SUK 44 3000 500        600 1000 1000 400  200 500  
SUK 45 3000         600 1000     3000  
SUK 46 3000          300       
SUK 47 400 1000  300   300   200 1000 1000 600  400   
SUK 48 2000 600 2000 400 700 500 400   4000 10000 4000 500 400  1000 700 
SUK 49 2000 1000 2000       2000 900 2000 1000  600 300 400 
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SUK 50  600  200      1000 2000 200 200  200   
SUK 51 3000 300 200       1000 2000 200 400  200 600 300 
SUK 52 7000 5000 3000 4000 2000 3000 2000   8000 4000 5000 4000 1000 3000 4000 3000 
SUK 53 2000         10000 10000       
SUK 55 200         400 200     600  
SUK 56 1000         400 600 1000  200    
SUK 58 400         200 200 300      
SUK 59          200  300      
SUK 60 500                 
SUK 61           400 2000      
SUK 62 2000 500  400  400    2000 1000   300    
SUK 64 9000         600        
SUK 65 1000         200 200  200  200 200  
SUK 66 900 400 300       600 600  600  300   
SUK 67 1000 700 200       600 1000  1000  1000  4000 
SUK 68 1000 1000 200 400 300 200    1000 11000 600 2000  1000  300 
SUK 72          600        
SUK 73 1000         900 2000 200      
SUK 76 2000 2000  1000 1000 1000 1000   1000 2000 1000 1000 2000 500  600 
SUK 79 300 400        1000 700       
SUK 80 3000 300        2000 1000 500     300 
SUK 81 900         300 400       
SUK 83 600         300        
SUK 85  400 900 900 600 800 600   3000 13000 600  500 300 1000 500 
SUK 86 900 800 200       900 1000 800 600 200    
SUK 87   300               
SUK 88 1000  200       1000 1000 800      
SUK 89 300         300 2000       
SUK 90 900 300        1000 1000 2000     600 
SUK 93 3000 1000 1000 1000 1000 1000 1000   5000 4000 700 1000 1000 400 900 1000 
SUK 94 4000 2000 900 3000  2000 2000   4000 4000 1000 300 3000 2000 1000 900 
SUK 95            1000      
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SUK 98 4000  200       900 5000       
SUK 102                  
SUK 103 200          600       
SUK 105 1000  200       900 2000       
SUK 108 200  600   300     400       
SUK 109 300  300       2000 900    200   
SUK 110 300  400 200              
SUK 113 1000         500 4000       
SUK 115           600 3000      
SUK 116 300         300 500     300  
SUK 118 400 800   400 200 200   2000 2000  400     
SUK 119  2000 1000 900  800 200   2000 4000 3000 5000  2000 1000 2000 
SUK 120                  
SUK 122   500       1000 200       
SUK 127 900         300 2000 300 300     
SUK 128    2000 1000 2000 2000   2000 2000   3000   6000 
SUK 130                  
SUK 131 600         800 600  500     
SUK 134 700 400         500 600 500   2000 300 
SUK 135   900    1000   400 900  400     
SUK 136 1000          6000 900      
SUK 136   1000         200      
SUK 137 700          200 7000      
SUK 139 2000 700  600 200 400    2000 2000 600 1000   200 400 
SUK 142   800        400       
SUK 143 2000         1000 3000 200      
SUK 144  200 400 200 300     600 600 600     300 
SUK 147  500 200   700 3000    1000  500  300  300 
SUK 150 1000 200 200 300  400    600 500 200 300 200 300 200 200 
SUK 151 1000 2000 300 1000 600 700 2000   1000 1000 1000 1000 900 2000 300 300 
SUK 152 1000 2000   600     1000 700 300 400  1000 600  
SUK 159 500 200        300 600 3000      
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SUK 185 1000 1000        2000 1000 3000   800   
SUK 190 1000    400 700 400   600 400    500   
SUK 195 1000 500         600  800  500   
SUK 196  500  1000 2000 1000 3000   200    3000 500   
SUK 199 4000   1000 2000     9000 2000   3000 500   
SUK 210           200 400      
 
Table 1. ELISA endpoint titers of semi immune adult sera tested on different DBL domains. 
Adult sera tested on 15 different DBL domains. Left column: serum sample names. Top row: isolate names IAM (Ifakara 
Asymptomatic malaria) ISM (Ifakara Severe Malaria). Numbers in the table indicate the reciprocal endpoint titers. No number 
indicates that the serum is negative for the DBL domain tested. Colors: white, negative serum; yellow, endpoint titer 200-600; orange 
700-2000; red over 2000. 
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Table 2. ELISA endpoint titers of children sera tested on different DBL domains. 
 
   IAM11 IAM5 IAm7 IAM12 IAm17 IAM18 IAM10   ISM3 ISM51 ISM16 ISM48 2 ISM33 ISM48 ISM11 ISM49 
  BC583                                 
  BP123 3000 1000 1000 1000 1000 1000 1000   5000 4000 700 1000 1000 400 900 1000 
  BC626                                 
  BP125                                 
  BC623       1000 700 1000 700   4000       1000       
  BP146       2000 1000 2000 1000           1000       
  BC619                                 
  BP162                                 
  BC640                                 
  BP182                                 
  BC582                                 
  BP096                                 
  BC568                                 
  BP076                     200           
  BC600                                 
  BP161                                 
  BC598                                 
  BP071                     200           
  BC569                                 
  BP083 600               300               
  BC609 200                               
  BP074 900 800 200           900 1000 800 600 200       
  BC572     200                 200     300   
  BP131 900               300 400             
  BC612 200 400                             
  BP159                     300           
  BC561                                 
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  BP157                                 
  BC552 900               200               
  BP177                                 
  BC575 200                 300             
  BP091 300               300 2000             
  BC648 600                   300           
  BP145                 400               
  BC574 300               200 200             
  BP073 3000 400             2000 1000 500         300 
  BC642                                 
  BP114                                 
  BC599                                 
  BP166                                 
  BC565 200                               
  BP116                                 
  BC559       10000 5000 1000 5000           9000       
  BP107       500 600   200       600   1000       
  BC646                                 
  BP140 5000                               
  BC617                                 
  BP108                                 
  BC548                                 
  BP078                                 
  BC554 1000                               
  BP120                                 
  BC624                 200   700           
  BP127                                 
  BC578                                 
  BP085 2000 2000   1000 1000 1000 1000   900 2000 1000 1000 2000 500   600 
  BC573                                 
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  BP075 1000               900 2000 300           
  BC586                                 
  BP165     200           1000 1000 700           
  BC555                       300   800     
  BP128                                 
  BC566                                 
  BP070           800 200         400 300       
  BC645                             200   
  BP134                                 
  BC643     400                           
  BP170                   200             
 
Table 2. ELISA endpoint titers of children sera tested on different DBL domains. 
Children sera were tested on 15 different DBL domains. Left column: serum sample names of matched samples: BCXXX (baseline 
sample), BPXXX (6 months sample). Top row: isolate names IAM (Ifakara Asymptomatic Malaria) ISM (Ifakara Severe Malaria). 
Numbers in the table indicate the reciprocal endpoint titers. No number indicates that the serum is negative for the DBL domain 
tested. Colors: white, negative serum; yellow, endpoint titer 200-600; orange 700-2000; red over 2000. 
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Figure 3. Graphic representation of differential recognition of severe and 
asymptomatic DBL domains. 
 
TOP. Left: recognition frequencies for asymptomatic DBL domains. Right: 
recognition frequencies for severe DBL domains. Bottom. Frequency of recognition 
depending on their origin. The number of sera recognizing asymptomatic DBL 
domains is highest for “1 DBL recognized group” (arrowhead). For the case of 
severe DBLS the recognition frequency peak is shifted and peaks at 2 DBL domains 
recognized (arrow).  
 
The difference in recognition frequencies between DBL domains from severe cases 
and asymptomatic cases is highly significant (Score Test for Trends equivalent to 
chi-squared test for trend, p=0.002). This test only calculates with total numbers. 
Using the Wilcoxon signed-rank test, which takes pairing into account (ie each 
0  1   2   3  4   5   6   7         0   1   2   3  4   5   6   7 
295 
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individual has a value for severe and a value for asymptomatic) leads to the same 
conclusion (Prob > |z| = 0.0002). (Figure 3). 
 
Recognition of severe DBLS does not correlate with age 
To investigate whether frequency of recognition was correlated with age, we tested 
this correlation using the Spearman’s Rank test. The age of the enrolled adults from 
which the serum samples were collected varied from 11 to 64 and the average was 
32,9 years. As shown in Figure 4, there is no evidence of correlation between total 
number of recognitions and age (p-value 0.8825) using Spearman's Rank correlation 
coefficient.  
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Figure 4. Age dependence of frequency of recognition. 
In A the results for asymptomatic DBL domains are shown and in B the frequency of 
recognition for severe DBL domains are shown. There was no correlation of age and 
frequency of recognition. 
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Borderline evidence for different recognition between the sexes 
From the 100 sera samples from semi immune adults, 48 sera were from female and 
52 sera from male adults. To test if recognition frequency of DBLs was sex 
dependant, data were further analysed to investigate if there is a correlation 
between the sex of the semi immune adult and the recognition frequency. Using the 
score test for trends, we calculated that there is some borderline evidence that the 
overall frequency of recognition was different between the sexes (p-value 0.0669). 
This indicates an inhomogenous distribution of recognition frequencies depending 
on sex. However an obvious trend is not visible (Figure 5). 
 
 
Figure 5. Testing sex dependence of recognition frequencies.  
The X-axis represents the number of times a sera recognized DBL domains (sum of 
severe and symptomatic). The non-homogenous distribution in some recognition 
groups is obvious. I.e. group 2 and 8 are represented by more males than females 
and in groups 1 and 5 it is vice versa. 
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ELISA results from children sera 
Sera samples from children from Africa (Tanzania, Ifakara) were collected in a 
logitudinal study in 1996. 34 sera samples for two time points (baseline and 6 
month) were tested. No children in this study had a malaria episode in between the 
two time points. The dynamics of antibody titers against different DBL domains was 
measured in ELISA tests  (see Table 2). In general, the frequency of positive sera 
and the endpoint titers of children sera were lower compared to those of adult sera. 
At the baseline, 25 sera did not recognize a single DBL domain, six month later only 
18 samples were completely negative. Only one serum (BP123) recognized all DBLs 
tested. The most often recognized DBL domain was IAM11 with 25%. The three 
most rarely recognized antigens were ISM48, ISM11, ISM49 (4.5% each). It was 
calculated that for the baseline samples 34 recognitions occurred out of 510 tests 
(34 sera x 15 antigens= 510), which is 6.6%. Among those positives were 15 
positive for severe DBL domains and 19 for asymptomatic DBLs.  
Six months later 78 positive tests were counted, which is 15.3%. Those 78 positive 
tests split into 45 positive for severe DBL domains and 33 for asymptomatic DBL 
domains. Not only the number of positive sera increased overall. It is noteworthy 
that the increase of recognized “asymptomatic DBL” domains is only 14 (+73.7%), 
whereas for the “severe DBL” domains it is 30 (+200%).  
Recognition frequencies were calculated similar to adult sera and represented in 
Figure 6. The 34 paired sera from baseline and 6 month later were tested on 7 
asymptomatic and 7 severe DBLs. The recognition frequencies for asymptomatic 
DBL domains did not change in this 6 months period as shown by the blue bars in 
Figure 6.  In contrast, the frequency of severe DBL recognition increased 
significantly (p<0.0001, Fisher's Exact test). This is shown by the red bars in Figure 
6. 
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Figure 6. Follow up sera from children tested on severe and asymptomatic DBL 
domains. 
Frequencies of recognition of different DBL domains by children are shown as bar 
graphs. 4A: ELISAs on asymptomatic DBL domains tested with sera at baseline and 
6 months later. 4B: Severe DBL recognition frequencies are shown at the baseline 
and after 6 month.  The children sera recognized more severe DBLs after 6 months 
than on baseline, as can be seen by the increase of the high frequency recognition 
groups (3-7), which come up only for severe DBLs after 6 month. (40 Sera are 
shown here, the 6 additional are unpaired sera) 
(In blue sera from baseline, in red sera from 6 month later.) 
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Chapter 4 
 
Discussion 
Previously we have isolated full length var mRNA from blood samples from patients 
with severe malaria episodes and from age matched asymptomatic children. The 
DBL 1α domain of PfEMP1 was amplified from cDNA, cloned and sequenced.  
Here we have recombinantly expressed 14 dominant and 1 minor DBL domain from 
14 patients in E.coli. Seven dominant DBL domains for each group 
(severe/asymptomatic) and one minor from the severe group. We have measured 
antibody titers of 100 semi-immune adult sera from PNG against these 15 
recombinant DBL domains by ELISA. With this method we calculated recognition 
frequencies of the sera against the severe versus the asymptomatic DBL domains. 
Briefly, we found that DBL domains derived from severe isolates were more 
frequently recognized than DBLs from asymptomatic infections (see graph 1).  
Furthermore, we tested children sera from a longitudinal study at baseline and 6 
months later. We found that the general recognition frequency was dramatically 
lower compared with the adults (graph 4). Additionally we found that the antibodies 
aquired by the children during the 6 months period were stronger directed against 
the severe DBL domains than against the asymptomatic DBL domains. 
 
The choice of DBL domains 
From a previous study we had a set of cloned DBL domains isolated from severe 
and asymptomatic children from Tanzania (unpublished, Paschal Mugasa). These 
sequences were cloned from full length var mRNA as described in [55]. We have 
sequenced 50 clones per isolate. We chose the most frequently cloned DBL domain 
for expression. Difficulties occurred for very complex samples where a prominent 
clone was not obvious. This was the case for ISM49, ISM16, IAM10 and IAM18. In 
these isolates about 20 different sequence groups (98% homology) were found per 
isolate. For example the most prevalent sequence in ISM49 was found 9 times and 
the next frequent was found 8 times. Even though the prominent clone in these 
samples was not significantly more numerous than others, we always chose the 
most frequent. In other less complex samples like IAM12 the difference was more 
obvious: 19 occurrences of the most prominent sequence and 4 of the second most 
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frequent. We also included a minor clone from ISM48 with only 3 findings (compared 
to 13 for the prominent). No obvious difference in titers was found for the minor 
clone compared with the major clones (see table 3). The minor clone was excluded 
for further statistical analyses because the role of the minor clones in an infection is 
not clear. However, we isolated parasites from peripheral blood, which per se do not 
necessarily seem to reflect the whole genotypical parasite load in an infected 
individual but certainly does not reflect the phenotypical parasite load [109, 110].  
 
Difference in proteins and difference in recognition 
All DBL domains in this experiment contain conserved sequences at the N and C 
terminal end (N terminal: ARSFADIGDII and C terminal: WFEEWAEDL). These short 
conserved stretches do not seem to be good epitopes, as titers among DBLs are 
dramatically different. When comparing relationships in sequence alignments with 
recognition frequency in ELISA we found differences.  For DBL ISM3 and ISM51, 
which were the most frequently recognized antigens, alignments revealed that these 
two isolate were closely related. This was reflected in the ELISA results. However, in 
the case of ISM48 (recognized 39 times) and IAM5 (recognized 19 times), the 
alignment revealed a close relationship (see alignment 1, results, chapter4), however 
the ELISA showed differential recognition. It seems that even small differences in 
amino acid composition can be enough to change the recognition pattern.  
 
 
Cloning and protein expression in E.coli 
We cloned the DBL domains in a pQE16 plasmid. This plasmid expresses the 
cloned gene as a 5` fusion to a mouse DHFR (dihydrofolate reductase) gene. The 
recombinant protein has the domain structure NH2-DHFR-DBL-HIS-COOH and had 
a calculated mass of 36kDa. It was necessary to express the DBL domain as DHFR 
fusion protein because expression with a single HIS-tag resulted in very low 
expression levels. The DHFR fusion was originally designed for expression of small 
peptides or toxic proteins, however in our case it enhanced the expression 
dramatically. This might be due to the greater stability of the mRNA or because the 
DHFR masks toxic domains or structures of the recombinant DBL domain. Neither 
the rare E.coli tRNA codons used by Plasmodium nor the high AT content seemed 
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to be important for high expression levels, as this was not altered with the DHFR 
fusion. We reached expression levels ranging from 0.5-4mg of recombinant protein 
from a 50ml culture. Beside the expression vector we found that rich medium (i. e. 
Terrific broth) is favored compared to normal LB, as the bacteria can grow to higher 
densities. 
The recombinant protein was totally insoluble. That made it necessary to apply two 
purification steps. First, all soluble and Triton-X-100 soluble proteins were 
eliminated. This resulted in a very pure fraction of inclusion bodies, which was then 
purified further using a Nickel column. These modifications resulted in very pure 
highly concentrated (up to 2mg/ml) recombinant protein. It was stated earlier that 
successful expression of plasmodial proteins in E.coli was dependent on the 
isoelectric point (pI) and size of the protein [83]. In our case neither of those had an 
influence on protein solubility, pre-termination nor expression levels. Also late 
induction time in the early stationary phase, which favors solubility [79]  had no 
effect.  
The DHFR fusion protein was also expressed without DBL domain as a negative 
control for downstream experiments. Recombinant DHFR is mostly insoluble. About 
90% of the expressed protein is in inclusion bodies, the rest can be purified under 
native conditions. Here we purified the insoluble fraction to follow the same 
conditions as for the DBL domains. The ODs obtained in ELISA for DHFR were 
generally around 0.2 (the positive control was 2 -3). The mouse DHFR used in this 
experiment is closely related to human DHFR with only little point mutations, thus it 
was expected that the titers against DFHR are very low (see Figure  2, lane D). 
 
ELISA on recombinant proteins 
Using recombinantly expressed proteins in ELISA experiments harbors intrinsic 
questions. The use of the same protein modifications system of the heterologue 
expression environment is more than doubt full. A lot of cell surface proteins are 
glycosylated, and this is also true for Plasmodium (as reviewed in [113] and 
commented in [114]). In Plasmodium proteins can be N- or O- linked glycosylated or 
GPI (glycosylphophatidylinositol) anchored. If the native DBL domain is glycosylated 
is unknown. It is also unknown to what extend the recombinant DBL domain is 
modified. However, glycosylation of proteins accumulating in inclusion bodies is 
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very unlikely as glycosylation occurs in the endoplasmatic reticulum (ER) lumen and 
insoluble protein aggregates have never entered the ER. It is further known that 
disulfide bonds stabilize the structure of the DBL domain. In the recombinant protein 
there is no formation of disulfide bonds as this is impossible in the reducing 
environment of the E.coli cytoplasm (reviewed in [115]), however disulfide bridges 
can be introduced by dialyzing in buffers containing red/ox components. We were 
aware of the improper folding of our recombinant protein and thus we do not claim 
that the antibodies binding our antigens have necessarily a role in vivo, as the 
antibodies detect most probably only linear epitopes. However, if recognition of the 
rDBL domians would be random due to their linear structure, we would not have 
found significantly different recognition patterns between severe and asymptomatic 
DBL domains. It is possible that important domains within the DBL are unstructured 
in the native protein as predicted for many plasmodial proteins [116].   
 
Calculation of titers 
Equal coating of different proteins was measured with a commercial monoclonal 
mouse anti-6xHIS tag IgG. Maximal titers of the positive controls were very high 
ranging from OD 2-3.5. Calculated half maximal titers of the mAB were around 
1:10`000. Coating efficiencies varied merely between experiments. As each sera was 
tested on all DBLs in the same experiment the variation between experiments is 
negligible for the comparison of titers between antigens.  
The negative control, a pool from 5 European blood donors, was approximately OD 
0.2 for the lowest dilution. The threshold was calculated from the mean of the 
negative titers plus 3 standard deviations.  Titers measured for the recognition of 
rDHFR were subtracted from the titers obtained for the rDBL domains.  
 
Antibodies against a subset of PfEMP1 variants prevent disease 
In graph 1 we showed that sera from semi immune adults recognize severe DBL 
domains more frequently than asymptomatic DBLs. As it is known that these semi-
immune adults are hardly suffering from severe malaria, we can conclude that their 
repertoire against severe DBL domains seems to contribute to protection against 
severe malaria. 
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Our findings with adult sera support the general hypothesis that different PfEMP1s 
with different functions exist and thus antibodies against different PfEMP1s can 
have more or less protective effects against severe malaria. If a human has an 
antibody repertoire against a subset of var genes coding for PfEMP1 variants that 
mediate cytoadherence in deep tissue e.g. brain, heart and lung, this human might 
be protected from severe malaria. Consequently, the library of antibodies against 
PfEMP1s that do not or to a lower extend (or in not as sensible tissues as the brain) 
mediate cytoadherence can be deficient without resulting in disease. Organs from 
fatal severe malaria patients are heavily infected with late stage parasites whereas 
organs from asymptomatic subjects contain almost no late stage parasites even 
though their parasitaemia were very high in peripheral blood samples [110].  
 
Recognition of severe DBL domains does not correlate with age 
To investigate whether frequency of recognition was correlated with age, we tested 
this correlation as shown in Graph 2. There is no evidence of correlation between 
total number of recognitions and age (p-value 0.8825) using Spearman's Rank 
correlation coefficient. We included age in our analysis because it can have a 
confounding effect in statistical analysis and because the antibody repertoire 
increases with age. This is especially pronounced in children when they develop 
their immunological protection. The correlation between age and protection from 
malaria has been already described by Ross and Koch over 100 years ago [117]. 
The age correlation is extensively reviewed in [118]. Recent chemoprophylaxis trials 
found that young children (2-12 month) treated prophylactically with anti malarials 
for a year and followed up for four years were at higher risk of a severe episode than 
the placebo group [119]. The reason might be the missing contact with the 
Plasmodial antigens during the time of treatment. At the time when 
chemoprophylaxis was stopped, the placebo group had already established a 
considerable protection against severe disease. However, in our adult group this 
phenomenon was not expected to contribute to the differential recognition of 
antigens as the median age is 32 and the youngest individual was 11 years old. All 
these individual are considered to be clinically immune. 
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Borderline evidence for different recognition between the sexes 
To test if recognition frequency of DBLs was sex dependant, data were further 
analysed to investigate if there is a correlation between the sex of the semi immune 
adult and the recognition frequency. We found that there is some borderline 
evidence that the overall frequency of recognition was different between the sexes 
(p-value 0.0669). Among our 100 sera tested 52 were from men and 48 from 
women. There are reports that men are generally more susceptible to parasitic 
infections than females [120]. Although the incidence of infection is similar the 
intensity and the parasitaemias are higher in men [121]. The only confirmed major 
sex difference in malaria is PAM in which parasites show a differential recognition 
pattern to placental CSA. Sera from multigravid women bind to parasites isolated 
from placentas whereas no male sera recognize these parasites [24]. In our 
experiments we did not expect gender-dependant difference in. The DBL domains 
tested here are isolated from children and we do not have a PAM associated 
PfEMP1-variant (which would be DBLγ). The inhomogeneous distribution of 
recognition frequency maybe comes from the sample number not being high 
enough. A trend for a differential recognition among males and females is not 
obvious (see graph 3). 
 
ELISA results from children sera 
Sera samples from 34 children from Africa (Tanzania, Ifakara) were collected in a 
follow up study in 1996. 34 sera samples for two time points (baseline and 6 month) 
were tested. In general, the frequency of positive sera and the endpoint titers of 
children sera were lower compared to those of adult sera. This what we have 
expected as children have lower IgG levels. The comparison of the two time points 
showed an increase of recognition with time. The increased recognition is not 
distributed equally between asymptomatic and severe antigens. The DBL domains 
derived from severe samples show a higher increase of recognition than the 
asymptomatic. This goes together with the results from the adult sera where the 
recognition of severe antigens is also higher. It is also postulated that parasites 
responsible for severe disease are the “common” parasites. Bull et al. showed by 
serum agglutination that parasites isolated from severe cases are readily 
agglutinated by heterologous sera [89]. Parasites from asymptomatic infections are 
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less frequently recognized. Thus it is conceivable that the children acquired some 
infections (from “common” parasites) during the six months period against which 
they developed antibodies. This theory is highly contrary to the assumption that the 
“common” parasites induce severe malaria in an unprotected individual, however 
non of the kids had a episode within the study. But reality might be more 
complicated and complex because not every child falls severely sick with an 
infection of a common variant. Otherwise there would be many more severe cases. 
The results obtained from the children follow up sera fit into the picture of the 
acquisition of clinical immunity to severe malaria, but the development of the 
antibody response cannot be explained satisfactorily and remains to be elucidated. 
 
Outlook 
It is still not obvious which modifications in the DBL domain are necessary to enable 
the parasite to prevent eradication by the immune system but remain cytoadherent. 
At the same time it is not clear if antibody levels against special DBL domains are 
enough to acquire semi-immunity. The DBL domain is often used to monitor 
expression variants of PfEMP1 [102, 109] but it is only a small part (130aa) of the 
large PfEMP1 (3000 aa) protein. The critical binding domain can easily be 
somewhere else in this or even another protein. It clearly needs further work, maybe 
including the whole protein in the analysis. As sequence analysis of the linear amino 
acids did not reveal conserved domains, it must be expanded into structural 
analysis.  
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Chapter 5: 
General discussion and conclusions of this thesis 
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General discussion and conclusions of this thesis 
 
The core objective of the present thesis was the investigation of conserved domains 
in PfEMP1 responsible for the pathology of severe malaria. Despite the growing 
body of knowledge the decisive point what makes some variants of PfEMP1 more 
virulent than other remains unknown. We expanded our experiments from long 
recombinant proteins over a very complex random PfEMP1 cDNA library to a more 
goal-orientated DBL-serology approach. The difficulties in recombinant expression 
of plasmodial proteins and the minute amounts of material obtained from field 
samples forced us to reconsider our approaches over and over. The final 
assessment of titers against severe and asymptomatic DBL domains however is a 
new way of investigating host parasite interaction. In previous experiments the 
influences of sera were tested on whole iRBC thus never revealed the sole role of 
PfEMP1. In our approach we used a new way to test antigens derived from different 
clinical cases on the same sera rather then different sera on the same antigen. To 
our knowledge this is the first time that the antigen was the basis of differential 
recognition. We could show that adults recognize more frequently DBL domains 
coming from severely sick patients compared to antigens coming from 
asymptomatic infections. This may indicate that even the DBL1α domain is a crucial 
epitope for the parasite to manage cytoadherence and to be the target of antibodies 
protecting from disease. Of course, questions concerning the choice of the right 
DBL domain extracted from very complex infections can be asked. Recombinant 
protein expression in heterologous systems like E.coli implicates doubts in 
conformation and modification of the peptide. But these complicacies account for 
both the severe and the asymptomatic DBL domains. With our experiments we 
show that recombinant protein expression can be useful in the assessment of titers 
against various antigens. These and other findings (like var2CSA in PAM) concerning 
protection from severe malaria by the recognition of specific domains from a 
variable antigen give hope to the possibility of the development of a disease 
preventing vaccine. Considering the pathological significance of PfEMP1, 
intervention in sequestration, cytoadherence and rosetting represent ideal targets 
for a morbidity reducing vaccine. 
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The way to such a vaccine however is still long and rough. Recombination of the 
variant antigens must be considered. We currently believe that the repertoire of var 
genes is endless and is not static. The blocking of certain domains by vaccine 
induced antibodies can easily induce the rise of new variants. More knowledge is 
needed on sequence information of the whole protein and on the mechanisms of 
antigenic variation. And PfEMP1 is not the only protein on the surface of an iRBC. 
Other proteins like the riffins or stevors may also account for cytoadherence and 
must be included in future analyses.  
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Appendix 1 
 
Sequences of recombinant DBL domains 
 
DBL domains were expressed as DHFR-DBL-6xHIS fusion proteins. The 
recombinant DHFR protein contains also the 6xHIS tag. Numbers in brackets give 
the calculated mass and the isoelectric point of the fusion protein (kDa;pl) 
 
>DHFR-6xHIS 
MRGSGIMVRPLNSIVAVSQNMGIGKNGDLPWPPLRNEFKYFQRMTTTSSVEGKQNLV
IMGRKTWFSIPEKNRPLKDRINIVLSRELKEPPRGAHFLAKSLDDALRLIEQPELASKVD
MVWIVGGSSVYQEAMNQPGHLRLFVTRIMQEFESDTFFPEIDLGKYKLLPEYPGVLSE
VQEEKGIKYKFEVYEKKGSRSHHHHHH (23;9.34) 
 
The following dbl domains replace the red sequence: 
 
>IAM5 
ARSFADIGDIVRGTDMFLGSNKEKEKIENSLQNIFKNIKKNNKKLKDLTDKQIREYWWA
LNRKEVWKALTCSVPYEAYYFTYKSDNFRTFSGYWCGHYEGAPPTNLDYVPQFLRWF
EEWAEDL (35;8.97) 
 
>IAM7 
ARSFADIGDIVRGKDLFLGHKQGKQKLEASLKTMFQNIQSTIDQLKRLSIDAVREYWWE
INRQEVWKAITCSAGEDDTYSKYLGDRTTGVSHGQCGHMDENVPTYFDYVPQFLRWF
EEWAEDL (35;6.84) 
 
>IAM10 
ARSFADIGDIIRGKDLFIGYDEKDRKEKKQLQQNLKNIFGKIHSEVTNGSNAEAAKARYK
DTTDFYQLREDWWDANRETVWEAITCGAAGGTYFRATCSDEENKSTLASNKCRCAG
KNADQVPTNFDYVPQYLRWFEEWAEDL 
(37;7.13) 
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>IAM11 
ARSFADIGDIIRGKDLYRGNSKEKDNLEKKLIEYFQKIHGGLTGDAQTHYNDKSGNFFK
LREDWWDANRQEIRNAIICDVPEDAKYLEQSDGSQSGSHQTKCRCHSGSVLTNFDYV
PQYLRWFEEWAEDL 
(36;6.87) 
 
>IAM17 
ARSFADIGDIVRGKDLFYGNPQEKKQRKELDKKLKEVFGKIHEGLKNGKAKERYKDTT
NYYQLREDWWTANRETVWKAITCAAKVGDTYFMESRTNSYKFSGDKCGHNDDNVPT
NLDYVPQYLRWFEEWAEDL 
(36;8.91) 
 
>IAM12 
ARSFADIGDIIRGKDLYLGDNRKDREQKVKLENKLKEIFAKIHENLGTQDAIGHYEDAKK
NYYKLREDWWTANRGTVWKAITCGAGKHDKYFRKTCNGGSPTKGYCRCNGDQPND
HKANIDPPTHFDYVPQFLRWFEEWAEDL 
(37;8.95) 
 
>IAM18 
ARSFADIGDIVRGKDLYIGNRKEKEKEELQKNLKSIFKKIYGELKNGKTNGEAAKVHYQE
DGQNYYKLREDWWTANRETVWEAITCNAGGGTYFRGTCGKNDTWTREDCRCDGSN
WPTYFDYVPQYLRWFEEWAEDL 
(37;8.20) 
 
>ISM49 
ARS FAD I GD I VRGRDLFLGNT YE S AQRDQLDKKLKE I F TQ I YND VTTNGKKP 
ALQKRYKKDGKDPDFFKLREDWWYANRQEIWKAITCKVENAQYFKDTCSTGGHYEK
CRCNGDQPKSGKGGDVNIVPTYFDYVPQYLRWFEEWAEDL 
(38;8.81) 
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>ISM51 
ARSFADIGDIIRGKDLYLDHEPGKQHLEERLERIFANIQKENGDINTLKPEEVREYWWAL
NRVQVWKAITCRAEEKDIYSRIAGDTTIWNDNCGHHVNQDVPTNLDYVPQYLRWFEE
WAEDL  
(35;6.19) 
 
>ISM16 
ARSFADIGDIIRGRDLF 
YGNTQEKTKRKQLDKKLKDIFGDIYKELRKNGKKGELQKRYQKDGDKDFFQLREDW
WEENRETVWKAITCDAPPDAQYFRGTCGDNEKTATQTPSQCRCNDDQVPTYFDYVP
QYLRWFEEWAEDL 
(38;8.20) 
 
>ISM48_1 
ARSFADIGDIVRGTDMFLGSNKEKEKIENSLQNIFKNIKKNNKKLKDLTDKQIREYWWA
LNRKEVWKALTCSVPYEAYYFTYKSDNFRTFSGYWCGHYEGAPPTNLDYVPQFLRWF
EEWAEDL  
(35;8.97) 
 
>ISM48_2 DEL 
ARSFADIGDIIRGKDLYLDHEPGKQHLEERLETMFQNIQYNNTELKNIPLPKVREYWWA
LNRGQVWKAITCHAGKDDAYFRNSSGGEYKFTSGYCGRNEGKVPTNLDYVPQHLRW
FEEWAEDL  
(35;7.82) 
 
ISM11 
ARSFADIGDIIRGKDLFIGNNKRDKLEKQLKEYFKNIYDNLNGAQKHYSDDDKGTKN Y 
YQLREDWWALNRQEIWKALTCESGGGRYFRETCAGGTSRTQDDCRCRTNDVPTYFD
YVPQYLRWFEEWAEDL 
(36;8.21) 
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>ISM3 
ARSFADIGDIIRGKDLYLDHEPGKQHLEERLERIFENIKKKNNNNELNNLSLDKFREYW
WALNRVQVWKAITCRAEEKDIYSKTTDNGKLLLWNYNCGHHVNKDVPTNLDYVPQFL
RWFEEWAEDL  
(36;7.81) 
 
>ISM33 
ARSFADIGDIIRGKDLFLGHEQRKKYLEARLEAMFDNIKKNNKKQLGELSTAQVREYW
WALNRGQVWKAITCGATMNDISFKNIGNGKLLLWNEKCGRGDYNLLTNLDYVPQFLR
WFEEWAEDL  
(35;9.16) 
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Appendix 2 
 
Peptide sequences: 
ATS1: SDITSSESEYEELDINDIYVP 
ATS2: PKYKTLIEVVLEPS 
ATS3: GIDLINDTLSSGNHIDIYDEVLKRKENELFG 
ATS4: LDRHRDMCEKWKNKEDILNKLKEEWNKENINN 
 
Primer sequences 5 --> 3 
 
pGEX_fwd: gggctggcaagccacgtttggtggt 
pGEX-reverse_MCS: atgcggccgctcgagtcg 
 
pQE_fwd: cccgaaaagtgccacctg 
pQE_reverse: gttctgaggtattactgg 
 
pTrcHis2_reverse: gatttaatctgtatcagg 
pTrcHis2_fwd: gaggtatatattaatgtatcg 
 
dbl1α_fwd: GCGTCCTCTCTGAGGCACGAAGTTTTGCAGATATAGG 
dbl1α_reverse: catGGATCCaAAGTCTTCGGCCCATTCCTCGAACCA 
 
ats beads: 
TCHTCMGAAAGTGARTATGAAGAATTGGATATTAATGATATATATGYACCAGGRAT
WGAAGTRGTAYTWGAACC-Biotin 
 
NTS_FCR_fwd: gaattcgcgacttcaggaggtagtgg 
NTS_FCR_reverse: gcgaagcttgccacggattccttttgctg 
 
 
ATS_FCR3_fwd: gaattcaagaaaaaaccawakcatctgttg 
ATS_FCR3_reverse: nnnnnngcggccgcnngatattccatatatctgatatagg 
 
 136 
SMART_PCR_primer: aagcagtggtatcaacgcagagt 
SMARToligo: ggtatcaacgcagagtacgcggg 
SMART_random: ggtatcaacgcagagtacnnnnnnnnn 
SMART_polyT: ggtatcaacgcagagtactttttttttttt 
 
F1: ggtgtgtgtatgcctccaagaag 
F2: acgagctcaaatggtgaggacaggaggtagcgg 
F3: acgagctcaaatgacatcatgtagtccggag 
F4: acgagctcatggcggctgcaggaagtggagg 
F5: acgagctcaaatggtacggtcgtcacgcg 
F6: acgagctcaaatggcgaggccaggtagcgg 
F7: acgagctcaaatggcgactggtagtgggggcg 
 
R1 
ttttccttttgcggccgcttagttagttacttctaggwggcatacatgctcc 
R2 
ttttccttttgcggccgcttagttagttactt ctg ggt ggc aca cac gca cc 
 
R3 
ttttccttttgcggccgcttagttagttactt ctt gga ggc ata cam rma cc 
 
R4 
ttttccttttgcggccgcttagttagttactt ctt gga ggc ata yak kca 
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Abbreviations 
 
ATS  Acidic terminal sequece 
BSA  Bovine Serum Albumin 
CIDR  Cysteine rich inter domains region 
CPE  chromosom central var promotor element 
CR1  Complement receptor 1 
CSA  Chondroitinsulfate A 
DBL  Duffy binding like 
DHFR  Dihydrofolate reductase 
DNA  Deoxyribonucleic  acid 
DTT  Diithiotreitol 
EDTA  ethylenediaminetetraacetic acid 
ELISA  Enzyme linked immuno fluorescence assay 
ER  Endoplasmatic reticulum 
FoR  Frequency of recognition 
GPI  Glycophosphatidylinositol 
GST  Glutathione S-transferase 
IAM  Ifakara asymptomatic Malaria 
IFA  Immuno flouresence assay 
IL  inter leukine 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
iRBC  Infected red blood cell 
ISM  Ifakara severe Malaria 
KAHRP Knob associsated histidine-rich protein 
kDa  kilo Dalton 
KLH  Keyhole Limpet Haemocyanin 
LB  Luria Bertani (lysogeny broth) 
MACS Magnetic cell sorter 
MAHRP Membrane associated histidine-rich protein 
NTS  N-terminal segment 
PAGE  Polyacrylamide Gel electrophoresis 
PAM  Pregnancy associated malaria 
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PBS  Phosphate buffered saline 
PCR  Polymeras chain reaction 
PEXEL Plasmodium export element 
PfEMP1 Plasmodium falciparum Erythrocyte Protein 1 
PMSF  phenylmethanesulphonylfluoride 
PNG  Papua New Guinea 
RBC  Red blood cell 
RNA  ribonucleic acid 
SDS  Sodiumdodecylsulfate 
SPE1  Subtelomeric var promotor element 
STI  Swiss Tropical Institute 
TBE  Tris Borate EDTA 
TE  Tris EDTA 
TNF  Tumor necroses factor 
UV  Ultra Violet 
vs  versus 
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